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ABSTRACT 
 
High-Oleic Ground Beef and Risk Factors for Cardiovascular Disease in Men and 
Postmenopausal Women. (May 2012) 
Ghazal Ghahramany, B.S., Shiraz University, Iran 
Chair of Advisory Committee: Dr. Stephen B. Smith 
 
 About half of all deaths in developed countries are caused by cardiovascular 
disease. It is well known that cardiovascular disease (CVD) risk can be influenced by 
diet, but optimal dietary content of fatty acids continues to be debated. The effect of fatty 
acid composition of ground beef on selected cardiovascular disease risk indicators was 
evaluated with two primary goals. The first goal was to document effects of ground beef 
fatty acid composition on plasma lipoprotein concentrations, whereas the second goal 
was to determine the effects of ground beef fatty acid composition on gene expression in 
peripheral blood mononuclear cells (PBMC). In both studies the results were compared 
between men and women. 
             Twelve men and women over age of 45 out of initially 15 completed a two-way 
crossover design. Subjects consumed five, 114-g ground beef patties per week for 5-wk 
periods separated by a 3-wk washout period. Patties contained on average 20% fat and 
monounsaturated fatty acid (MUFA): saturated fatty acid (SFA) of 0.8 and 1.1 for low-
MUFA (conventional) ground beef high-MUFA (premium) ground beef patties, 
respectively. Blood was collected from each subject before and at the end of each diet 
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period. Overall, the ground beef interventions decreased total plasma cholesterol, 
triacylglycerol, and very low density lipoprotein (VLDL) cholesterol. Plasma 
concentrations of high density lipoprotein (HDL) cholesterol and low density lipoprotein 
(LDL) cholesterol decreased and increased, respectively with premium ground beef 
consumption. The change in HDL cholesterol was significant in women but not in men 
suggesting that premium ground beef consumption had a greater impact on women than 
in men. 
For the second goal PBMC were isolated and the expression of selected genes 
was quantified by real-time PCR. ATP-binding cassette A1, ATP-binding cassette G1, 
and low-density lipoprotein receptor relative expression was increased with premium 
ground beef consumption. A significant increase was seen in stearoyl-Coenzyme-A 
desaturase 1 expression after premium ground beef treatment. With the exception of 
stearoyl-Coenzyme-A desaturase 1, all these genes were down-regulated with 
conventional ground beef consumption. Both sterol regulatory element binding 
transcription factor 1 and mediator complex subunit 1 were down-regulated after each 
beef patty treatment, but the effect was significant after consuming conventional ground 
beef. This suggests that genes involved in cholesterol metabolism were down-regulated 
with conventional ground beef consumption; whereas genes related to lipogenesis were 
up-regulated with premium ground beef consumption. From these data we concluded 
that different ground beef dietary interventions have different impacts on the PBMC 
gene expression that is related to cholesterol metabolism, inflammation and liver X 
receptor pathways. 
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CHAPTER I 
INTRODUCTION: THE IMPORTANCE 
OF RESEARCH 
 
CVD & Atherosclerosis 
            Cardiovascular disease (CVD) remains the single leading cause of death in both 
men and women. CVD risk assessment begins with a close examination of genetic 
modifiers such as age, sex and family history, as well as non-genetic environmental 
modifiers for instance smoking, alcohol and diet. It is well known that CVD risk can be 
influenced by diet, but optimal dietary content of fatty acids continues to be debated. 
Atherosclerosis, a type of arteriosclerosis (often referred to as hardening of the arteries) 
is responsible for the majority of CVD events; therefore considered to be the major 
contributor to CVD. Complications of atherosclerosis are the most common causes of 
death in Western societies. Atherosclerosis is defined as a form of chronic inflammation 
which begins with the initiation of endothelial dysfunction and involves interaction 
between monocyte-derived macrophages, T cells, the normal cellular elements of the 
arterial wall and modified lipoproteins. Some of the factors that lead to endothelial 
dysfunction can be mentioned as mechanical injury, toxins and oxygen radicals (1). This 
inflammatory process can ultimately result in the development of complex lesions or 
____________ 
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plaques inside the arterial lumen. Plaque rupture and thrombosis lead to the acute 
clinical complications of myocardial infarction and stroke (2). According to 
epidemiologic studies many genetic and environmental risk factors have been involved 
in the development of atherosclerosis; however elevated levels of serum cholesterol have 
been shown to have the major impact even in the absence of other known risk factors (2, 
3). Molecular mechanisms that control cholesterol biosynthesis and serum cholesterol 
levels were elucidated by Goldstein and Brown in 1977. Statins, a potent class of 
cholesterol lowering drugs were then developed and the development of these drugs 
significantly reduces cardiovascular mortality in hypercholesterolemic patients (4, 5). 
 
Disease Prevalence 
According to 2011 updates from Heart Disease and Stroke Statistics report by the 
American Heart Association,  an estimated 82, 600, 000 American adults (more than 1 in 
3) have  or more types of CVD. Of these, 40, 400, 000 are estimated to be over 60 years 
of age. Total CVD includes diseases listed in the bullet points below (6). 
 
● High blood pressure (HBP)—76, 400, 000 (defined as systolic pressure >140 mm Hg 
and/or diastolic pressure> 90 mm Hg, use of antihypertensive medication, or being told 
at least twice by a physician or other health professional that one has HBP) 
● Coronary heart disease (CHD)—16, 300, 000 
— Heart attack— 7, 900, 000 
— Chest pain— 9, 000, 000 
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● Heart failure—5, 700, 000 
● Stroke— 7, 000, 000 
 
Mortality  
Mortality data show that CVD as the underlying cause of death, including 
congenital cardiovascular defects, accounted for 33.6% of all 2,423, 712 deaths in 2007, 
or one of every three deaths in the United States. On average, 2,200 Americans die of 
CVD each day, an average of one death every 39 seconds. CVD claims more lives each 
year than cancer, chronic lower respiratory diseases (CLRD), and accidents combined 
(6). 
 
Lipoprotein, CVD and Atherosclerosis 
            Cardiovascular risk is not only related to total plasma cholesterol concentration 
but also to the relative proportion of cholesterol carried in individual ipoprotein 
fractions. A triad of increased blood concentrations of small, dense low density 
lipoprotein (LDL) particles, decreased high-density lipoprotein (HDL) particles, and 
increased triglycerides lead to Atherogenic dyslipidemia. (SFA) Obesity, insulin 
resistance, and type 2 diabetes mellitus can all lead to atherogenic dyslipidemia which 
has emerged as an important risk factor for myocardial infarction and cardiovascular 
disease (7). While a positive relationship exists between LDL cholesterol and CVD risk, 
HDL cholesterol has an inverse relationship and is therefore considered as protective.  
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            The liver is a major site of synthesis of both cholesterol and triacylglycerol and 
plays a key role in regulating the availability of lipid to the other tissues of the body by 
modulating lipid synthesis and the uptake and secretion of lipoproteins (8, 9). When lipid 
supply exceeds the ability to mobilize lipid the liver has the capacity to store relatively 
large amounts of both cholesterol ester and triacylglycerol. In terms of lipoprotein 
metabolism, the liver is the site of assembly and secretion of VLDL and the major site of 
removal of chylomicron remnants, intermediate-density lipoprotein (IDL) and LDL from 
the circulation. It synthesizes and secretes apolipoprotein (apo) A1, the major protein 
component of HDL, and actively removes cholesterol from the circulating HDL particles 
following interaction with cell surface receptors (10).  
 
High Density Lipoproteins 
            Clinical and epidemiological studies have consistently shown that plasma 
concentration of HDL is one of the most reliable negative risk factor for CVD meaning 
low plasma levels of HDL cholesterol (HDL-C) are strongly and independently 
associated with an elevated risk of coronary heart disease (CHD) (11). Furthermore, the 
concept of HDL quality rather than quantity, in other words HDL functionality versus 
HDL concentration in terms of its protective capability from atherosclerosis also has 
been the focus of increasing attention. The central role of HDL is reverse cholesterol 
transport (RCT), which is a pathway for removing excess cholesterol from cells and 
peripheral tissues, including the arterial wall, and transporting it to liver, the major organ 
for degrading and excreting cholesterol through the bile. RCT is widely considered the 
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major mechanism responsible for HDL-mediated atheroprotection (12). However, 
differences in the relative content of apolipoproteins and lipids in HDL makes plasma 
HDL particles highly heterogeneous in structure, composition and biological function. 
The main protein component of HDL is apolipoprotein A-I (apoA-I), a protein that 
contains eight amphipathic α-helical domains of 22 amino acids each.  
Lecithin:cholesterol transferase (LCAT) is the enzyme that generates most of the 
cholesteryl esters present in plasma and is activated by apoA-I. Cholesteryl esters are 
extremely hydrophobic and sequester into the core of the particles as they are formed; 
this effect converts discoid HDL into the large spherical HDL particles which 
predominate in normal human plasma. Spherical HDL particles are larger in size and in 
addition to a hydrophobic core of cholesteryl esters they contain triacylglycerols (TAG). 
There are two main subfractions of HDL particles which differ in density: large, light, 
lipid-rich HDL2 (density 1.063–1.125 g/mL) and small, dense, protein-rich HDL3 
(density 1.125–1.21 g/mL) (13). HDL2 and HDL3 can be further subfractionated into 
ﬁve distinct subpopulations of decreasing size: HDL2b, HDL2a, HDL3a, HDL3b and 
HDL3c (13); Moreover, HDL particles possess other potent biological activities, 
including anti-thrombotic, antioxidative, anti-inﬂammatory, anti-infectious and 
vasodilatory actions. Other atheroprotective properties of HDL include protection of 
endothelial function by stimulation of eNOS, stimulation of fatty acid oxidation, glucose 
uptake and insulin secretion (13, 14). 
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Low Density Lipoproteins  
            In human, the majority of serum cholesterol is carried by LDL particles. After 
TAG removal in peripheral tissues, a portion of the remaining LDL remnants are 
metabolized to LDL particles by further removal of TAG and dissociation of apo-
lipoproteins except for apoB100. The major physiological role of LDL is the delivery of 
cholesterol to peripheral tissues; however, increased levels of LDL cholesterol are 
positively correlated with increased risk of CVD. LDL is taken up by cells via LDL 
receptors. Decreased activity and/or expression of LDL receptors leads to accumulation 
of LDL in plasma; for instance, in patients with homozygous familial 
hypercholesterolemia (4).  Oxidative modifications in lipid and apoB components of 
LDL have been suggested to drive the initial formation of fatty streaks which result in 
atherosclerotic lesions. Macrophages and endothelial cells specialize in the uptake of 
modified LDL particles, which leads to the progression of atherogenesis. LDL particles 
may be modified in a number of different ways, including acetoecetylation, 
carbamylation, LDL-dextran sulfate complex formation, acetylation, malondialdehyde 
addition, oxidation, glycation and desialylation. However, not all modifications lead to 
increased uptake by the scavenger receptor. Oxidation of LDL particles may be the most 
studied mechanism in which LDL particles are modified and lead to increased uptake by 
the scavenger receptor. Like HDL, LDL are heterogeneous and can be defined on the 
basis of particle density, size, charge and chemical composition. LDL concentration, 
particle size and density are influenced by age, gender, hormone replacement therapy or 
contraceptive use, abdominal adiposity, diet and exercise. Small, dense LDL particles 
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with increased plasma TAG and low HDL-C are often associated with metabolic 
syndrome and diabetes mellitus secondary to insulin resistance (14, 15). It is still 
believed that small, dense LDL particles are a contributing factor to atherosclerosis 
based on evidence that smaller LDL are more suitable to penetrate arterial tissue (15) 
and are taken up less readily by LDL receptors (16). Furthermore, smaller LDL are 
oxidized at a greater rate than larger LDL particles (17).  
 
Very Low Density Lipoproteins 
            Formation and secretion of lipoprotein particles is primarily achieved in the 
intestine as chylomicrons and in the liver as VLDL. The assembly process of hepatic 
VLDL is initiated in the endoplasmic reticulum (ER) as soon as apoB100 is translated 
and translocated into the lumenal side. Each VLDL is composed of one molecule of 
apoB100, multiple other apolipoproteins, varied amounts of TAG and cholesteryl esters, 
depending upon the size of resulting particles. The synthesis and secretion of VLDL 
from the liver is largely governed by lipid substrate supply (18, 19). The expression of 
apoB100 appears to be largely constitutive. When sufficient TAG is available, the apoB 
is lipidated and a VLDL particle is formed. In the absence of sufficient TAG, the 
emerging apoB is degraded. Transfer of TAG onto apoB is mediated by the microsomal 
triglyceride transfer protein (MTP) (20). Evidence is emerging that certain 
polymorphisms in MTP may result in impaired functioning, reduced VLDL production 
and accumulation of lipid in the liver (8). When secreted, VLDL are large TAG-rich 
particles and contain apoB100. Once in circulation, VLDL acquire apoE and apoC (I, II, 
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and II). VLDL are delipidated by lipoprotein lipase, which is found on the surface of 
extra-hepatic tissues. The cholesterol, phospholipids and proteins that are hydrolyzed 
from VLDL triglycerides, are then transferred to higher density lipoproteins such as 
HDL and LDL, leaving a small, dense remnant lipoprotein (RLP). RLP are further 
metabolized to smaller more dense lipoproteins called IDL, which are remodeled to form 
the endproduct LDL. Both IDL and LDL can be recognized and cleared from plasma by 
LDL receptor due to the retention of apoB100. Hyperinsulinemia and increased free fatty 
acids secondary to insulin resistance lead to an increase in plasma TAG and VLDL 
concentrations. Although VLDL and TAG correlate strongly to LDL density and 
decreasing LDL size, these characteristics are inversely related to HDL-C especially the 
HDL2 subfraction (21, 22). 
            Several studies have shown that certain fatty acid species are preferentially 
utilized over others for VLDL assembly and secretion. For instance when McA-RH7777 
cells were cultured in the presence of exogenous oleate (18:1 n-9), TAG-rich VLDL 
were secreted many fold higher as compared to no oleate supplementation (23-25). 
However, when the cells were treated with polyunsaturated fatty acids (PUFA), 
assembly and secretion of TAG-rich VLDL was decreased (26). 
 
Inflammation and CVD 
            Several independent pathways of evidence now identify inflammation as a key 
regulatory process that links multiple risk factors for atherosclerosis and its 
complications with altered arterial biology. It’s been three decades since atherosclerosis 
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has been known as a proliferative process (27, 28). According to that concept, 
endothelial damage led to platelet aggregation and release of platelet-derived growth 
factor that would trigger the proliferation of smooth muscle cells in the arterial intima, 
and resulted in atherosclerotic plaque formation. Among the many biomarkers of 
inflammation proposed for diagnostic use, myeloperoxidase, Lp-PLA2, pentraxin-3, 
cytokines such as IL-6, proteases such as matrix metalloproteinase-9, and C-reactive 
protein (CRP) have generated considerable attention. CRP is measured by a highly 
sensitive assay (hsCRP) and for a variety of reasons CRP has emerged as a leading 
biomarker of inflammation for clinical application. Many prospective cohort studies 
indicate that hsCRP predicts incident myocardial infarction, stroke, and cardiovascular 
death (29-31). 
 Inflammation is also seen with conditions such as obesity, insulin resistance, 
hypertension, metabolic syndrome, type 2 diabetes, hypertriglyceridemia, low HDL 
cholesterol and smoking, all of which are correlated with increased CVD risk (32). For 
this reason, inflammatory proteins such as high sensitivity hs-CRP and interleukin-6 (IL-
6), when elevated chronically, are considered markers of CVD (33, 34). Furthermore, 
homocysteine is not an inflammatory protein but it is regarded as a biomarker strongly 
associated with CVD. A single mechanism by which homocysteine contributes to CVD 
is not established. Homocysteine may cause endothelial damage and dysfunction by 
affecting nitric oxide production and reactivity (35). Homocysteine activates platelets 
and promote expression of the CD40/CD40 ligand from activated platelets (36). 
CD40/CD40 ligand engages on the surface of endothelial cells, smooth muscle cells, or 
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macrophages triggers an additional inflammatory response, characterized by the release 
of inflammatory cytokines such as interleukins IB, and chemokines such as chemokine 
ligand 2 [CCL2] as well as expression of adhesion molecules such as E selectin, VCAMl 
and P selectin (36, 37). Elevated homocysteine levels are normally caused by either 
nutritional deficiencies in vitamin cofactors (folate, vitamin B12, and vitamin B6) or by 
genetic defects in the enzymes involved in homocysteine metabolism (37). Other factors 
affecting homocysteine metabolism include chronic kidney disease, hypothyroidism, 
psoriasis, certain cancers and several drugs such as theophylline and niacin (36).  
 
Genes Involved in Atherosclerosis and Inflammation  
            A number of genes have now been linked to the pattern of lipoprotein changes. 
Achieving a better understanding of the genetic and dietary influences underlying 
atherosclerosis and inflammation may be valuable in order to improved interventions to 
reduce the risk of CVD in high-risk individuals (7).  
            It has been well established that fatty acids can regulate the expression of a 
variety of genes involved in lipid and lipoprotein metabolism. This occurs through a 
number of pathways within the liver. Peroxisome proliferator activated receptors 
(PPARs), sterol regulatory element binding proteins (SREBPs) and liver X receptors 
(LXRs) are included in these pathways (38, 39). 
            Three transcription factor families have been found to play a major role in the 
regulation of hepatic gene transcription which is stimulated by dietary fatty acids. These 
include PPARα, LXR, and SREBPs. The PPARs and LXR play important roles in both 
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lipid metabolism and inflammation. These ligand-activated intracellular transcription 
factors bind to specific response elements within the promoters of genes as heterodimers 
with the retinoid X receptor (RXR). After binding to their ligands they form 
conformational changes which can facilitate interaction with co-activators and through 
recruitment of multiple factors involved in gene expression, this leads to activation of 
transcription (40). 
 
Peroxisome Proliferator-Activated Receptors 
            PPARs represent three isoforms, PPARα, PPARβ (also known as δ) and PPARγ, 
with PPARα being the predominant isoform in liver. These isoforms are encoded by 
different genes. PPARs are nuclear receptors that are regulated by fatty acids (41). As 
lipid sensors, they are primarily involved in regulation of lipid metabolism and 
subsequently in inflammation and atherosclerosis. Ligand activation of PPARα is 
associated with transcriptional up-regulation of a number of different genes for proteins 
associated with fatty acid oxidation and lipoprotein metabolism. Thease proteins include 
acyl coenzyme A oxidase, carnitine palmitoyl transferase, lipoprotein lipase, and 
apolipoproteins AI and CIII (42). PPARα expression is highest in tissues with high rates 
of fatty acid catabolism such as liver, kidney, heart, and skeletal muscle. Furthermore, 
PPARα has been implicated in ϐ oxidation of FAs as well as lipid metabolism. 
Activation of PPARα has been reported to improve levels of plasma TAG, HDL-C and 
the overall atherogenic plasma lipid profile, while PPARγ appears to play a role in 
adipocyte differentiation, lipid storage, fat metabolism, and glucose homeostasis, with 
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increasing evidence supporting its role as an important modulator of inflammation, 
atherosclerosis and macrophage differentiation (43). A diverse range of compounds act 
as ligands for the various PPAR isoforms. This includes both saturated and unsaturated 
fatty acids, though in general PUFA tend to be more potent. While all three PPAR 
subtypes have been shown to bind n-3 and n-6 PUFA, affinity appears to be greatest for 
PPARα, followed by PPARγ and PPARβ (43, 44). 
 
Liver X Receptors 
             LXRs have been described as sensors of cholesterol in the nucleus since they are 
activated by increased cholesterol concentrations inside the cell. Oxysterols 22-
hydroxycholesterol and 24, 25-epoxycholesterol and long chain fatty acids have been 
identified as ligands for LXRs (45). There are two LXR family members: LXRα and 
LXRβ.  LXRα is the most highly expressed isoform in the liver while LXRβ is expressed 
in most cell types, but not in hepatocytes (46). Like PPARs, LXRs bind to response 
elements as heterodimers with RXR. These transcription factors regulate the expression 
of genes involved in sterol and fatty acid metabolism, particularly hepatic bile acid 
synthesis, including adenosine triphosphate-binding cassette protein A1 (ABCA1), 
apolipoprotein E, lipoprotein lipase, cholesterol ester transfer protein, and phospholipid 
transfer protein (47). Studies have shown that chronic administration of LXR agonists 
considerably decrease lesion formation in both low-density lipoprotein receptor (LDLR) 
and apolipoprotein E knockout– mediated atherosclerosis mouse models (48). 
Macrophages are known to play key roles in lipid metabolism and atherosclerosis. And 
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they develop from the bone marrow (49). LXR agonists increase RCT from 
macrophages by increasing expression of macrophage apolipoprotein E and cholesterol 
efflux transporters ABCA1 and ABCG1 (ATP-binding cassette, subfamily A, member 1 
and ATP-binding cassette, subfamily G, member 1, respectively). ABCA1 is involved in 
reverse cholesterol transport; therefore, this can be an important part of the mechanism 
for LXR-dependent protection from atherosclerosis. At site of atherosclerotic lesions 
within macrophages, excess accumulation of cholesterol converts them into foam cells 
and accounts for the major portion of lesion deposited cholesterol (50). Thus, by 
stimulating RCT, LXR reduces foam cell formation and lesion cholesterol content. 
LXRs also play an important role in the regulation of genes involved lipogenesis as well 
as carbohydrate metabolism (51, 52). Moreover, evidence suggests that the regulation of 
lipogenesis by LXR is mediated mainly by its effects on SREBP1c expression (53, 54). 
PUFA have been reported to inhibit the interaction of oxysterols with LXR and thereby 
inhibit its activation of target genes (53, 54). 
 
Sterol Regulatory Element-Binding Proteins  
            A balance between the amount of cholesterol and the amounts of unsaturated and 
saturated fatty acids in phospholipids is required in order to keep the integrity of cell 
membranes. Membrane-bound transcription factors, called sterol regulatory element-
binding proteins (SREBPs) are responsible to maintain this balance and activate genes 
that encode enzymes of cholesterol and fatty acid biosynthesis (55). The SREBPs also 
enhance transcription of the LDLR, which mediates cholesterol uptake from plasma 
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lipoproteins (53). Unlike other transcription factors, the SREBPs are synthesized as 
membrane-bound proteins attached to the ER. Transcription of the LDLR occurs when 
there is low level of cholesterol inside the cells. During this time the SREBPs are 
transported to the Golgi complex. They are then processed by proteases to release a 
soluble fragment that enters the nucleus in order to activate transcription of the genes 
involved in cholesterol biosynthesis such as genes that encode HMG-CoA reductase and 
LDLR (54). 
            When LDL-derived cholesterol enters cells, it blocks the transport of SREBPs to 
the Golgi complex. This leads to blocking the release of the active fragment SREBPs 
from membranes (53). 
            SREBPs play a major role in regulating the expression of genes associated with 
lipid and lipoprotein metabolism (55, 56). Two SREBP genes produce three separate 
proteins (SREBP1a and 1c from one and SREBP2 from the other) with SREBP1c and 
SREBP2 being the predominant isoforms in the liver. Furthermore, PUFA have been 
shown to decrease nuclear SREBP-1 protein levels but it doesn’t have any effects on the 
levels of SREBP2 (57). Therefore, due to the role of SREBP1c in regulating lipogenic 
gene expression, it may be an important candidate for mediating the effects of PUFA on 
lipogenesis (58).  
            In vivo studies have shown that SREBP-1c stimulated transcription of hepatic 
lipogenic genes in response to insulin and high-carbohydrate feeding, whereas SREBP-2 
activated genes involved in cholesterol synthesis (59, 60). The stimulation of SREBP-1c 
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by LXR consequently activates the lipogenic pathway by activating genes involved in 
lipid synthesis, including the SCD1 gene (60). 
 
Stearoyl-Coenzyme A Desaturase 1  
            SCD1 is a delta-9-desaturase, iron-containing enzyme that catalyzes a rate-
limiting step in the synthesis of unsaturated fatty acids and is responsible for placing a 
double bond at carbon 9 of a fatty acid chain. The principal product of SCD1 is oleic 
acid (18:1(n-9)) that is formed by the desaturation of stearic acid. The ratio of stearic 
acid to oleic acid has been implicated in the regulation of cell growth and differentiation 
through its effects on cell membrane fluidity and signal transduction. SCD1 desaturates 
stearic acid and palmitic acid to produce oleic and palmitoleic acid (16:1(n-7)), 
respectively (61).  Even though many of the effects of SCD1 deficiency are dependent 
on diet composition and other genetic factors (62),  it seems SCD1 deficiency is 
antiatherogenic. SCD1 deficiency also promotes inflammation and atherosclerosis in 
mice (63). Studies of a mouse model with a targeted disruption in the SCD1 gene have 
suggested that SCD1 plays an important role in lipid homeostasis and lipoprotein 
metabolism. SCD1-deficient mice showed reduced synthesis of lipids, especially TAG, 
resistance to diet-induced weight gain, and reduced leptin deficiency-induced obesity 
(64, 65). Moreover, SCD1-deficient mice have low levels of TAG in VLDL (61, 64, 66). 
            An increased level of SCD1 activity in macrophages is positively correlated with 
increased palmitoleic acid, which explains the relief from lipid-induced ER stress. Erbay 
et al. (67) demonstrated endogenous fatty acid synthesis and desaturation of fatty acids 
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can be highly beneficial for defending ER function when macrophages are exposed to 
toxic lipids, which may lead to an antiatherogenic effect of SCD1 activity. Previous 
work has shown that when VLDL hydrolysis was inhibited, SCD1 deficiency 
significantly reduced VLDL secretion in leptin-deficient ob/ob mice, suggesting that 
SCD1 deficiency may also play a role in VLDL-TAG secretion (66). Oleic acid in TAG 
is a major component of VLDL particles, and any change in the availability of this 
MUFA may affect VLDL production. Furthermore, oleate produced by SCD1 leads to 
lipogenic gene expression through fructose-mediated induction suggesting an important 
role of oleic acid in lipid metabolism (68). 
 
Dietary Intervention and Atherogenic Dyslipidemia 
            Dietary recommendations to reduce the risk of CVD include lowering energy 
intakes of total fat, saturated fatty acids (SFA) and trans-fatty acids, in order to avoid 
their effects on raising cholesterol levels (69). The major SFA within beef (myristic acid, 
14:0, palmitic acid, 16:0 and stearic acid, 18:0) each have been found to be associated 
with CHD risk (70), although others suggest that a distinction should be made for stearic 
acid which has been found to have little cholesterol-raising effects in humans (71, 72). 
            It has been reported that dietary fatty acids directly regulate the expression of key 
enzymes involved in fatty acid synthesis such as acetyl coenzyme A carboxylase (ACC), 
fatty acid synthase (FAS) and SCD1 (73, 74). In animal models it has been shown that 
PUFA can significantly down-regulate expression of the genes for these enzymes (38, 
39). By contrast, it has been suggested that SFA may actually stimulate the expression of 
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these enzymes (73, 74). PUFAs have been recognized to be capable of depressing the 
expression of genes for enzymes involved in fatty acid synthesis, including ACC, FAS 
and SCD (38). These genes appear to be down-regulated by both n-3 and n-6 PUFA 
though response to n-3 may be more profound (38, 39). Trans-unsaturated fatty acids 
have been considered to be potent in their ability to increase blood concentrations of 
cholesterol (75). 
            Epidemiological observations clearly showed that populations with high dietary 
intakes of SFA had higher plasma cholesterol levels and an increased incidence of CVD 
(76). The major impact of SFA has been shown to be in increasing LDL-C (72, 77). 
            Due to the current recommendations, beef and beef fat and their effects on CVD 
have been examined closely. Though beef fat and coconut oil are both considered to be 
high in saturated fat, they do not have the same effects on cholesterol levels. When 
compared to coconut oil, which consist of more medium chain saturated fatty acids 
(lauric (12:0) and myristic acid (14:0)), beef fat reduced total, LDL, and HDL 
cholesterol (78). When red meat was tested against fish and poultry, there was no 
significant difference in plasma cholesterol concentrations between the diets consisting 
of red meat, fish or poultry (79). 
Analysis of a prospective cohort study, the Framingham Heart Study, confirmed 
that fat content in the diet, after multivariable adjustment for carbohydrate intake and a 
variety of other potential confounders, did not significantly affect LDL size or TAG 
levels in either men or women (80). This was true regardless of the quality of fat studied, 
total fat, SFA, MUFA, or PUFA content. However, a study by Campos et al. (81) 
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reported an associated reduction of LDL particle size with reduced animal fat intake and 
increased consumption of carbohydrates. LDL:HDL ratios are reduced when 
carbohydrate is replaced with fat, even with saturated fat (82). When isocaloric 
substitutions of carbohydrates for monounsaturated fat or polyunsaturated fat were made 
in the diets of women, their risk of CVD increased 20 and 60%, respectively (83). 
Changing the quality of the fat in the diet has been shown to be more beneficial than 
reducing the total amount of fat in the diet (82, 83). In conclusion, it remains unclear 
whether having high or low dietary carbohydrate content is more beneficial for 
cardiovascular health. 
In the year 2000, the Nutrition Committee of the American Heart Association 
moved away from its former insistence on low-fat diets (8-10% of energy) and 
concluded that diets that provided up to 40% of dietary energy in the form of unsaturated 
fat were as heart-healthy as low-fat diets. An outcome of this official opinion has been 
the reevaluation of the nutritional properties of a number of higher fat foods such as 
dairy, nuts, and dietary oils such as olive oil rich in the monounsaturated fatty acid, oleic 
acid (84). 
 
Beef Consumption and its Effect on Serum Cholesterol 
The relationship of beef consumption to its effect on lipoprotein variants and 
inflammatory markers related to CVD risk has not been adequately evaluated, 
particularly in post-menopausal women.  Reports linking dietary fat to serum lipoprotein 
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levels often have been interpreted to mean that the general public, especially those at risk 
for CVD, should consume diets containing little or no red meat.   
Scientists previously concluded that dietary SFA elevate serum cholesterol 
concentrations, whereas PUFA reduce serum cholesterol concentrations, and MUFA 
have little or no effect (85, 86).   The major MUFA in beef, oleic acid, has been studied 
in more detail and found to lower LDL-C without affecting the beneficial HDL-C (87, 
88).   This effect is most convincing when natural foods were used to supplement diets 
with oleic acid (89, 90).   Furthermore, in previous studies conducted in this laboratory, 
the level of HDL-C significantly increased after consumption of high oleic acid ground 
beef.  
One of the SFA in beef, stearic acid, either has no effect or may actually lower 
serum cholesterol (91, 92). Typically MUFA constitute 35 to 45% of the total fatty acids 
in beef produced in the U.S. (88, 93).   The wide variation of oleic acid content in market 
beef has been considered with inconsistent study results, with a decrease (94) in or no 
effect (95, 96) on serum cholesterol in human subjects.  
 
Benefits of Red Meat Consumption 
            Consuming moderate amounts of lean red meat, as part of a balanced diet, 
valuably contributes to intakes of essential nutrients iron, zinc and vitamin B12 and 
possibly to intakes of n-3 PUFA and conjugated linoleic acid (CLA).  Furthermore red 
meat is long established as an important dietary source of protein (97). 
 
  
20  
 
Fatty Acid Composition  
            Approximately 50% of the intramuscular fat of beef and lamb is made up of 
unsaturated fatty acids; MUFA, primarily oleic acid and PUFA, predominantly the 
essential n-6 and n-3 PUFA linoleic acid (LA, C18:2) and alpha-linolenic acid (ALA, 
C18:3), respectively (98). 
            The ratio of PUFA to SFA in beef is approximately 0.11 being much lower than 
the desired dietary ratio of 0.4, due to biohydrogenation of unsaturated fatty acids in the 
rumen (98). A meta-analysis has shown that increasing the dietary ratio of PUFA:SFA 
can lead to a reduction in plasma total cholesterol and as a result, there is much research 
focusing on ways to improve this ratio within meat (99). The fatty acid composition of 
meat varies by animal breed, age, sex, diet and within the cut of meat (100). 
 
Monounsaturated Fatty Acid 
Oleic acid is the main MUFA found in beef (93), but it typically is associated 
with olive oil and the Mediterranean diet. There are polyphenolic compounds in olive oil 
that also have an influence on lipid metabolism, in that they reduce HMG-CoA reductase 
activity (101). However the effect of olive oil on cholesterol metabolism was confirmed 
by Ruíz-Gutiérrez et al. (102) despite of the beneficial effects of the polyphenols found 
in olive oil (103). They observed an increase in HDL-C in hypertensive women who 
consumed a diet enriched with high-oleic sunflower oil or olive oil. Furthermore, a 
significant decrease in plasma HDL2 and an increase in plasma HDL3 cholesterol 
concentrations were seen with the oleic and interventions. In addition to an increase in 
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HDL-C, oleic acid reduces the post-secretory oxidation of LDL particles, making them 
less atherogenic (103). 
 
n-3 Polyunsaturated Fatty Acids  
            Lean tissue of red meat contains α-linilenic acid and the long chain n-3 PUFA, 
eicosapentaenoic acid (EPA, 20:5(n-3)), docosapentaenoic acid (DPA, 22:5(n-3)) and 
docosahexaenoic acid (DHA, C22:6). α-linilenic acid, derived mainly from plant 
sources, has been associated with a reduced risk of CVD by epidemiological studies 
(104). Its elongation products, the LCn-3 PUFA, are widely recognized for their many 
effects on heart health, vasodilation, anti-thrombotic effects and improving platelet 
aggregation (105). Long chain n-3 PUFA has other beneficial effects such as improving 
the function of central nervous system, retinal function and the inflammatory response 
(106). Studies have shown that meat consumers have greater plasma concentrations of 
long chain n-3 PUFA than vegetarians (107). 
 
Conjugated Linoleic Acid 
            Conjugated linoleic acid (CLA) is a term used to describe a group isomers of 
octadecadienoic acid, of which ruminant meat and milk are the major dietary sources 
(108). Concentrations of CLA have been found to range from 0.37 to 1.08 g/100 g 
within beef muscle (109). 
            CLA is formed through the ruminal biohydrogenation of dietary LA and also 
through an endogenous synthesis pathway from trans-vaccenic acid (TVA). The isomer, 
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18:2cis-9, trans-11 which is also known as rumenic acid, is the major and most 
important CLA isomer found in red meat (110). Its concentration within meat tissue is 
almost similar to n-3 PUFA (111). CLA has been found to have anti-carcinogenic and 
anti-atherogenic properties in several animal studies (112, 113). Long chain n-3 PUFA 
also has been found to favorably alter immune function in humans (114). 
 
Iron  
            Iron deficiency is one of the most prevalent nutritional deficiencies both in 
developing and developed countries. It has been estimated that at least 50% of women 
and children and 25% of men are iron deficient in poor countries. Most of the body’s 
iron is found as a component of a number of proteins, including enzymes, hemoglobin 
circulating in erythrocytes, and myoglobin in muscle (115, 116). Iron is essential for 
many cellular processes in the body and, as a component of haemoglobin, is necessary 
for maintaining adequate transport of oxygen in the blood. Therefore, even mild 
suboptimal status before the onset of anaemia can impact negatively on health (117). 
Heme iron found in meat is more bioavailable than non-heme iron found in plant 
sources; thereby meat consumers maintain better iron status than vegetarians and vegans 
(118). Furthermore red meat in particular is recognized as a significant source of heme 
iron compared to poultry and fish (119). 
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Zinc 
            Zinc on a molecular level, plays a major role in a variety of biochemical 
enzymatic processes relevant to maternal, fetal, infant and child health and survival. 
Women of reproductive age, the fetus, and young children are particularly at risk for 
deficiencies because of their high requirements for zinc. The main reason for zinc 
deficiency, particularly in the poor nations of the world, is the low intake of animal 
source foods (120). In relation to contribution of zinc, beef and lamb contain 4.1 mg and 
3.3 mg/100 g tissue (121) and, as a result, have been classified as rich sources (120). 
 
Vitamin B12 
            The risk of vitamin B12 deficiency is high in vegetarians, particularly in forms 
such as macrobiotic diets, which contain no foods of animal origin (122). Vitamin B12 is 
essential for normal blood formation and neurological development and function (123, 
124). All naturally occurring vitamin B12 in the diet is derived from bacterial synthesis. 
Intestinal bacteria synthesize the B12, which is absorbed by animals, mainly ruminants. 
The main advantage of animal source foods, particularly meat, is the high content and 
bioavailability of micronutrients; meaning, there is a high level of absorption and 
utilization by the body because of the presence of heme protein found only in meat, fish 
and poultry (123). Although some plant foods are relatively high in iron, zinc, or 
calcium, e.g., spinach and legumes, the micronutrients are poorly absorbed. The essential 
vitamins play an indirect but essential role in the synthesis of purines and pyrimidines, 
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transfer of methyl groups, synthesis of proteins from amino acids, and carbohydrate and 
fat metabolism (123). 
            Red meat is certainly the major dietary source of B12 in the diet, providing over 
two thirds of the daily requirement in one 100 g serving (118). B12 is required by active 
enzymes within the methylation cycle and low intakes of B12 as well as folate and 
vitamin B6 have been associated with elevated homocysteine, which is a risk factor for 
CVD and stroke (105, 125). This was confirmed in a cross-sectional study that 
consumers with high intakes of total meat compared to vegetarians have lower 
homocysteine levels (105). 
 
Present Study 
            The objectives of this study were: 
1) Evaluate baseline metabolic and inflammatory responses to 
dietary interventions in men and post-menopausal women.  
2) Determine impact of ground beef diets containing different 
monounsaturated fatty acid:saturated fatty acid (MUFA:SFA) 
ratios on  lipoprotein and inflammatory markers.   
3) Examine the effects of ground beef diets containing different 
MUFA:SFA ratios on gene expression in human peripheral blood 
mononuclear cells (PBMCs). 
            My primary hypothesis was improving fatty acid profiles in ground beef by 
modifying MUFA:SFA ratio in beef through diet would differentially affect CVD risk 
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meaning  premium ground beef compared to conventional  ground beef would have 
beneficial impacts on CVD risk in men and post-menopausal women. Also, dietary 
induced mechanisms involved in the pathways leading to atherosclerosis were 
investigated by studying gene expression during ground beef patty consumption. 
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CHAPTER II 
HIGH-OLEIC GROUND BEEF AND RISK FACTORS FOR CARDIOVASCULAR 
DISEASE IN MEN AND POSTMENOPAUSAL WOMEN 
 
Introduction 
            Cardiovascular disease (CVD) is the leading cause of death in the United States.  
It is well known that CVD risk can be influenced by diet, but optimal dietary content of 
fatty acids continues to be debated. In 2000, the Nutrition Committee of the American 
Heart Association moved away from its former insistence on low fat diets and concluded 
that diets that provided up to 40% of dietary energy in the form of unsaturated fat were 
as heart-healthy as low fat diets (84).  An outcome of this official opinion has been the 
re-evaluation of the nutritional properties of a number of higher fat foods such as dairy, 
nuts, and dietary oils such as olive oil rich in the monounsaturated fatty acid, oleic acid 
(126).  
The relationship of beef consumption to its effect on lipoprotein variants and 
inflammatory markers related to CVD risk has not been adequately evaluated, 
particularly in post-menopausal women.  Reports linking dietary fat to serum lipoprotein 
levels often have been interpreted to mean that the general public, especially those at risk 
for CVD, should consume diets containing little or no red meat.   
Scientists previously concluded that dietary saturated fatty acids (SFA) elevate 
serum cholesterol concentrations, whereas polyunsaturated fatty acids (PUFA) reduce 
serum cholesterol concentrations, and monounsaturated fatty acids (MUFA) have little 
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or no effect (85, 86).   The major MUFA in beef, oleic acid, has been studied in more 
detail and found to lower LDL-cholesterol without affecting the beneficial HDL-
cholesterol (87, 127).   This effect is most convincing when natural foods were used to 
supplement diets with oleic acid (89, 90).   Furthermore, in previous studies conducted in 
this laboratory, the level of HDL-cholesterol significantly increased after consumption of 
high oleic acid ground beef.  
One of the SFA in beef such as stearic acid either has no effect or may actually 
lower serum cholesterol (91, 92).   Typically monounsaturated fatty acids constitute 35 
to 45% of the total fatty acids in beef produced in the U.S. (88, 93).   The wide variation 
of oleic acid content in market beef has been considered with inconsistent study results, 
with a decrease (94) in or no effect (95, 96) on serum cholesterol in human subjects.    A 
dose-response relationship was established between the MUFA:SFA ratio in beef that is 
consumed and plasma lipoprotein cholesterol and inflammatory markers of CVD. 
       This study focused on the relationship among differences in the ground beef 
MUFA:SFA ratio and serum total lipoproteins, lipoprotein subfractions and 
inflammatory markers associated with increased CVD risk.   LDL and HDL particle 
diameter will be used to identify the presence of particularly atherogenic LDL or anti-
atherogenic HDL (128-130). 
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Methods 
Overall Design 
            This study involved 7 women and 5 men (45-75 years of age) who have been 
assigned randomly to consume ground beef of a specific MUFA:SFA ratio.  The ground 
beef sources included inexpensive chub pack ground beef with a MUFA:SFA ratio of 
0.8 and Wagyu ground beef (Heartbrand) with a MUFA:SFA ratio of 1.1.  At study 
entrance, each subject underwent a complete history and physical exam by a physician 
and baseline measurements of a complete lipid profile including LDL and HDL 
subfractions, hs-CRP, insulin, and glucose after 12 hours of fasting.  Subjects were asked 
to complete a 4-d diet record.  Participants were then randomized to one of two groups: 
1) ground beef with MUFA:SFA ratio of 0.8 or 2) 1.1.  Ground beef was delivered to 
individual homes for storage and consumption.  Participants were asked to complete two 
4-d diet records during the first 5 wk. At the end of 5 wk blood samples was collected.  
Following the first dietary modification period, the participants restarted a free range diet 
for 4 wk.  During this time they completed a 4-d diet record. At the end of this “washout 
period”, the participants started on the second diet modification for 5 wk.  The 5-wk 
period included the third diet record completion. 
Dietary Design 
Subjects  
The study protocol was reviewed and approved by Texas A&M University 
Institutional Review Board for the use of human subjects in research and all participants 
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gave written consent. Nine postmenopausal women and six men were recruited from the 
local Bryan/College Station, Texas community. Seven women and five men completed 
the study. The subjects included men over age 45 and women whose last menstrual 
period was over 1 y prior to enrollment of the study by natural or surgical means with or 
without ovaries. Subjects did not have history of CVD, stroke or diabetes, had normal 
liver function tests, normal fasting glucose, and serum total cholesterol of less than 6.72 
mmol/L, and not taking lipid lowering drugs. Baseline characteristics of the participants 
are presented in Table 1. Participants were contacted at least once a week by e-mail or 
telephone to provide updates and encourage compliance. 
 
Table 1     Baseline characteristics for subjects1 
  
Item Mean SE  
Age, y 62.6 2.3  
Body weight, lb 76.2 6.8  
Body mass index, kg/m2 26.8 0.9  
Android fat, % total fat 44.5 1.8  
Gynoid fat, % total fat 41.09 2.6 
Total body fat, % 36.1 2.1  
1Data are means ± SE for 5 men and 7 women. 
 
 
 Preparation of Ground Beef 
 A survey of the local supermarkets by this laboratory at Texas A&M University 
has demonstrated that ground beef of the required specifications is readily available.  
Typical chub pack or ground round has MUFA:SFA ratios ≤ 0.90, whereas branded beef 
has MUFA:SFA ratios of close to 1.1.  Akaushi beef, which was supplied by 
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HeartBrand, has a MUFA:SFA just over 1.3.  This knowledge of different variations in 
market beef was used to produce the desired fatty acid compositional targets.  
            The ground beef was transported from local retail outlets on ice to Texas A&M 
University Rosenthal Meat Science and Technology Center.  The ground beef was 
processed and packaged according to industry standards under HACCP control in the 
federally inspected Rosenthal Meat Science and Technology Center.  Ground beef was 
formed into 114-g patties, vacuum packaged, and frozen at the Texas A&M University 
Rosenthal Meat Science and Technology Center.  Beef patties were picked up vacuumed 
packaged and frozen from Texas A&M University to each participant.       
 
 Processing of Blood for Analysis 
 Blood sampling was obtained by certified phlebotomists that were assigned to 
the research project. Blood was collected from an arm vein prior to initiation of the 
dietary treatments, at the end of each diet phase. Plasma was harvested from the blood 
collected with 15% EDTA. Serum for standard lipid assays was collected into serum-
separation vacutainer tubes. All serum and plasma samples were stored at -80°C. 
 
Fatty Acid Composition of Plasma and Test Ground Beef 
 Fatty acids were measured in the baseline plasma, plasma taken after 5 wk of 
each test beef treatment. Additionally, fatty acid composition, along with total fat and 
moisture of the dietary ground beef patties were measured. Total lipid was extracted and 
methylated as described (131, 132). Fatty acid methyl esters were analyzed with a 
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Varian gas chromatograph (model CP-3800 fixed with a CP-8200 autosampler, Variam 
Inc., Walnut Creek, CA). Separation of fatty acid methyl esters was accomplished on a 
fused silica capillary column CP-Sil88 [100m x 0.25mm (i.d.)] (Chrompack Inc., 
Middleburg, The Netherlands) with helium as the carrier gas (1.2 mL/min). Oven 
temperatures began at 150°C and were increased to 160°C at a rate of 1°C/min. The 
oven temperature rose further to 167°C at a rate of 0.2°C/min. The temperature 
increased a rate of 1.5°C/min to a final temperature of 225°C where it was held for 26 
mins. Injector and detector temperatures were at 270°C. Individual fatty acid methyl 
esters were identified using genuine standards (Nu-check Prep, Inc., Elysian, MN and 
Sigma-Alderich Co.) and expressed as a g/100 g total fatty acid methyl esters analyzed 
or as g/100 g hamburger patty. The low-MUFA ground beef patties were made from 
chub pack ground beef, purchased from a local retail outlet with a MUFA:SFA ratio of 
0.9. The high-MUFA patties were made from Akaushi ground beef (Heartbrand Beef, 
Yoakum, TX) with a MUFA:SFA ratio of 1.3 (Table 2). 
 
Lipoprotein Analysis 
 Serum aliquots kept at -80°C were sent to SpectraCell Laboratories, Inc. 
(Houston, TX) for complete lipoprotein density and particle number analyses. A 
complete “Lipoprotein Particle Profile™” test was provided using the lipoprotein 
subgroup particle number analysis method. Lipoprotein particles were stained with a 
fluorescent dye and separated utilizing a patented continuous gradient over a range of d 
= 1.00 – 1.30 g/cm3 generated by analytical ultracentrifugation. Once separated, the 
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fluorescence of the lipoprotein particles was measured in a high performance liquid 
chromatography type flow system. For processing the fluorescence response was 
normalized to a cholesterol scale with a proprietary algorithm. Values corresponding to 
each lipoprotein subgroup at their specific densities were determined using a multiple 
Gaussian fit/integration routine (133). 
 
Diet Records  
Prior to each diet phase, and once during each phase, participants completed a 4-
d record (to include one weekend day). The diet records were analyzed for nutrient 
composition to establish baseline observations, and encourage compliance with total 
patty consumption requirement. The records were analyzed using Nutribase version 7 
(CyberSoft, Phoenix, AZ). 
 
Statistical Analysis 
 Data were analyzed as a paired t-test, comparing baseline (habitual) values to 
values after 5 wk on the test diet.  Thus, each participant served as her/his own control.  
Because each participant randomly rotated through all three diets, reported values are 
means ± standard error of the mean (SE) for n = 12 observations. 
 
Results 
 
Dietary records indicated that when on a test diet, participants consumed a lesser 
amount of total MUFA and oleic acid. This was not in patterns consistent with their test 
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ground beef interventions. Also, there were no significant differences in cholesterol and 
carbohydrate intake; however protein intake increased significantly with conventional 
ground beef consumption according to diet analysis (Table 3).   
 
TABLE 2 Fatty acid composition Conventional (Low MUFA) and Premium 
(High MUFA) ground beef patty1 
Fatty acid Low MUFA High MUFA 
g/100-g ground beef patty 
Total lipid   22  17 
14:0 (myristic) 0.86 0.59  
14:1 (myristoleic) 0.21 0.23  
16:0 (palmitic) 6.50 4.89  
16:1 (n-7) (palmitoleic) 0.91 0.96  
18:0 (stearic) 4.07 2.31  
18:1 (trans-11) (trans-vaccenic) 0.40 0.21 
18:1 (n-7) (cis-vaccenic) 0.38 0.41 
18:1 (n-9) (oleic) 9.72 8.33  
18:2 (n-6) (linoleic) 0.54 0.41  
MUFA:SFA ratio    0.8 1.1 
1Data are means for three batches of ground beef per treatment group. 
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TABLE 3 Total daily energy intake per day from major nutrients for habitual diets 
(Baseline) and for test diets of women rotated through test ground beefs low 
in monounsaturated fatty acids (Conventional) or high in monounsaturated 
fatty acids (Premium)1 
Nutrient Baseline Conventional Premium  
Total energy, kcal 1,876 ± 142 1,926 ± 223 1,814 ± 358 
Protein, g 59.00 ± 8.06 89.76 ± 8.06** 71.11 ± 8.1 
Carbohydrate, g 231 ± 34.1 212 ± 38.6 236 ± 58.3 
Fat, g 64.3 ± 7.58 78.7 ± 9.69 67.5 ± 17.1 
Saturated fat, g 20.5 ± 2.67 27.3 ± 3.88 23.8 ± 6.28 
Monounsaturated fat, g 21.09 ± 2.95 27.1 ± 3.1 22 ± 5.64 
Polyunsaturated fat, g 10.4 ± 1.37 11.7 ± 1.68 11.2 ± 3.4 
Trans-unsaturated fat, g 0.85 ± 0.67 0.25 ± 0.12 0.34 ± 0.28 
Cholesterol, mg 283 ± 65.1 293 ± 40.6 206 ± 58.9 
Oleic acid, g 18.04 ± 2.47 23.0 ± 2.8 17.7 ± 4.47 
Linoleic acid, g 7.49 ± 1.07 8.75 ± 1.54 9.18 ± 3 
Linolenic acid, g 0.83 ± 0.15 0.89 ± 0.12 0.58 ± 0.13 
Eicosapentaenoic acid, g 0.07 ± 0.03 0.04 ± 0.02 0.004 ± 0.002 
Docosahexaenoic acid, g 0.14 ± 0.07 0.09 ± 0.04 0.007 ± 0.003 
Fiber, g 13.7 ± 1.6 13.6 ± 2.29 15.0 ± 3.23 
Sugar, g 90.9 ± 24.8 75.4 ± 23.2 87.9 ± 22.8 
Sodium, mg 2,987 ± 402 2,595 ± 491 2,286 ± 397 
Potassium, mg 2,374 ± 185 2596 ± 322 2,265 ± 513 
Vitamin A, IU 4,399 ± 855 4236 ± 1008 4,258 ± 1974 
Vitamin C, mg 188.14 ± 91.13 100.75 ± 29.14 82.01 ±31.26 
Calcium, mg 573 ± 66.6 720 ± 121 588 ± 105 
Iron, mg 16.3 ± 2.98 14.82 ± 2.85 16.55 ± 4.2 
Thiamin, mg 1.47 ± 0.24 1.39 ± 0.24 1.59 ± 0.36 
Riboflavin, mg 1.76 ± 0.26 1.94 ± 0.28 1.86 ± 0.46 
Niacin, mg 29.0 ± 8.62  21.04 ± 2.96 19.53 ± 5.32 
Folate, µg 380.7 ± 79.1 348.7 ± 68.8 343.8 ± 100.0 
1Data were derived from 4-d diet records, including one weekend day, collected during each test 
period. Data for the habitual diet were obtained at baseline before patty consumption began. 
 Data are means ± SE for 12 men and women.  ** P ≤ 0.05 
 
Total cholesterol concentration decreased after consumption of both type of beef 
patties but the changes were not significant. LDL-C concentrations was decreased after 
conventional ground beef treatment and increased after Premium ground beef treatment. 
However, the changes were not significant. HDL-C concentration was significantly 
decreased after premium ground beef consumption and increased after conventional beef 
patty consumption (Table 4 and Figure 1). Serum VLDL-C and TAG   concentrations 
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were increased with the consumption of the conventional ground beef patties and 
decreased with the consumption of premium ground beef patties while RLP and IDL 
particle concentrations increased after conventional ground beef consumption; however 
none of these changes were significant (Table 5 and Figure 2). 
 
TABLE 4       Major lipoprotein cholesterol concentrations (mmol/L) for men and 
women rotated through test ground beefs low in monounsaturated fatty acids 
(Conventional) or high in monounsaturated fatty acids (Premium)1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium  
Baseline Premium  Final 
Total 
cholesterol, 
mmol/L 
5.55 ± 0.28  
 
5.37± 0.24 
 
5.34 ±0.27 
 
5.08 ±0.20 
 
LDL, mmol/L 5.55 ± 0.28  
5.37 ± 0.24 
 
3.14 ± 0.23 
 
5.08 ± 0.2** 
 
HDL, mmol/L 1.58 ± 0.11   
0.76 ± 0.16 
 
    1.80 ± 0.11 
 
 1.51 ± 0.06** 
 
1 Data are means ± SE for 12 men and women. ** P ≤ 0.05 
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FIGURE 1 Changes from baseline in total cholesterol, LDL, and HDL 
cholesterol concentration (mmol/L) of men and women rotated through test ground 
beefs low in monounsaturated fatty acids (conventional) or high in 
monounsaturated fatty acids (premium). Values are expressed as mean ± SEM, n = 
12.  * P ≤ 0.01 (the significant change is between mean differences of low and high 
MUFA consumption). 
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TABLE 5       TAG, VLDL, RLP, and IDL cholesterol concentrations for men and 
women rotated through test ground beefs low in monounsaturated 
fatty acids (conventional) or high in monounsaturated fatty acids 
(premium)1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium 
Baseline Premium Final 
VLDL, mmol/L 0.35 ± 0.03  
0.31 ±0.03 
 
0.47 ±0.05 
 
0.35 ±0.04 
 
RLP, mmol/L 0.81 ±0.06  
0.94 ±0.07 
 
0.90 ±0.1 
 
0.91 ±0.1 
 
IDL, mmol/L 0.72 ±0.05  
0.85 ±0.06 
 
0.79 ±0.09 
 
0.81 ±0.09 
 
TAG, mmol/L 1.02 ±0.2  
0.78 ±0.06 
 
1.06 ±0.11 
 
0.87 ±0.09 
 
1 Data are means ± SE for 12 men and women. 
There were no significant differences among phases (P > 0.1) 
 
  
38  
 
 
FIGURE 2 Changes from baseline in triglycerides (TAG), intermediate 
lipoprotein (IDL), very low density lipoprotein (VLDL) and remnant lipoprotein 
(RLP) cholesterol concentration (mmol/L) of women rotated through test ground 
beefs low in monounsaturated fatty acids (conventional) or high in 
monounsaturated fatty acids (premium). Values are expressed as mean ± SEM, n = 
12.   
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LDL III, LDL IV, and LP(a) particle concentration did not show a significant 
change with consumption of both beef patty types (Table 7 and Figure 3). LDL particle 
size increased significantly with conventional ground beef consumption. No significant 
change was observed in LDL particle size after premium ground beef consumption 
(Table 6 and Figure 4). 
 
 
TABLE 6    LDL III, LDL IV, and Lp(a) lipoprotein cholesterol concentrations 
and LDL particle size for men and women rotated through test 
ground beefs low in monounsaturated fatty acids (Low MUFA) or 
high in monounsaturated fatty acids (High MUFA)1 
Lipoprotein  Low MUFA Baseline 
Low MUFA 
Final 
High MUFA 
Baseline 
High MUFA 
Final 
Dense LDL III, 
mmol/L 
0.59 ± 0.06 
 
0.53 ±0.03 
 
0.62 ±0.09 
 
0.53 ±0.03 
 
Dense LDL IV, 
mmol/L 
0.20 ±0.01 
 
0.20 ±0.02 
 
0.21 ±0.02 
 
0.21 ±0.02 
 
Lp(a), mmol/L 
 
0.63 ±0.19 
 
0.65 ±0.19 
 
0.63 ±0.18 
 
0.50 ±0.14 
 
LDL (nm)     20.11 ±0.02   20.20 ±0.03**   20.10 ±0.04   20.16 ±0.03 
1 Data are means ± SE for 12 men and women. 
** P ≤ 0.05 
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FIGURE 3 Changes from baseline in LDL III, LDL IV, and Lp(a) cholesterol 
concentration (mmol/L) of men and women rotated through test ground beefs low 
in monounsaturated fatty acids (conventional) or high in monounsaturated fatty 
acids (premium). Values are expressed as mean ± SEM, n = 12. 
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Figure 4 Changes from baseline in LDL particle size (nm) of men and women 
rotated through test ground beefs low in monounsaturated fatty acids 
(conventional) or high in monounsaturated fatty acids (premium). Values are 
expressed as mean ± SEM, n = 12.  * P ≤ 0.01 (the significant change is between 
mean differences of low and high MUFA consumption). 
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HDL subfraction cholesterol concentration did not change significantly after 
consumption of either beef patty. HDL 2a and HDL2b decreased with premium ground 
beef consumption while HDL 3c increased after both premium and conventional ground 
beef consumption. The changes however were not significant (Table 7 and Figure 5).  
              
TABLE 7   HDL subfraction cholesterol concentrations for men and women 
rotated through test ground beefs low in monounsaturated fatty acids 
(conventional) or high in monounsaturated fatty acids (premium)1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium 
Baseline Premium Final 
HDL2a, mmol/L 
0.22 ± 0.05 
 
0.22 ±0.02 
 
0.25 ±0.04 
 
0.22 ±0.03 
 
Bouyant HDL2b, 
mmol/L 
0.70 ±0.11 
 
0.68 ±0.07 
 
0.70 ±0.09 
 
0.68 ±0.08 
 
HDL3c, mmol/L 
0.72 ±0.03 
 
0.75 ±0.03 
 
0.70 ±0.02 
 
0.73 ±0.02 
 
1 Data are means ± SE for 12 men and women. There were no significant differences 
among phases (P > 0.1) 
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FIGURE 5 Changes from baseline in HDL subfractions cholesterol 
concentration (mmol/L) for test diets of men and women rotated through test 
ground beefs low in monounsaturated fatty acids (conventional) or high in 
monounsaturated fatty acids (premium ). Values are expressed as mean ± SEM, n = 
12. 
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Conventional ground beef patty consumption had no significant effect on VLDL 
particle concentration. However, VLDL decreased after consumption of either premium 
or conventional ground beef (Table 8 and Figure 6). 
 
TABLE 8   VLDL and RLP particle concentrations for men and women rotated 
through test ground beefs low in monounsaturated fatty acids 
(conventional) or high in monounsaturated fatty acids (premium)1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium 
Baseline Premium Final 
VLDL, nmol/L 
 
52.66 ± 5.93 
 
44.83 ± 5.17 70 ± 8.64 55.25 ± 7.70 
RLP, nmol/L 134.58 ± 10.92 148.66 ± 13.65 148.41± 17.12 148.41 ± 16.26 
1 Data are means ± SE for 12 men and women.  
There were no significant differences among phases (P > 0.1) 
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FIGURE 6 from baseline in VLDL and RLP particle concentration (nmol/L) of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium). Values are 
expressed as mean ± SEM, n = 12 
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Though LDL cholesterol particle number was increased with the conventional 
ground beef intervention and decreased with premium ground beef consumption. 
However, none of these changes were significant. LDL III and LDL IV particle number 
concentration showed no significant changes after each diet (Table 9 and Figure 7).  
 
TABLE 9   LDL and LDL subfraction particle concentrations for men and 
women rotated through test ground beefs low in monounsaturated 
fatty acids (conventional) or high in monounsaturated fatty acids 
(premium )1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium 
Baseline Premium Final 
LDL Total, 
nmol/L 851.33 ± 55.08 903.5 ± 50.74 879.5 ± 68.60 866.5 ± 58.68 
Dense LDL III, 
nmol/L 
 
216.66 ± 25.31 
 
196 ± 13.23 227.75 ± 34.64 196.66 ± 13.92 
Dense LDL IV, 
nmol/L 99.416 ± 6.93 99.91 ± 10.97 103.91 ± 12.03 103 ± 10.47 
1 Data are means ± SE for 12 men and women. 
There were no significant differences among phases (P > 0.1) 
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FIGURE 7 Changes from baseline in LDL subfraction particle concentration 
(nmol/L) of men and women rotated through test ground beefs low in 
monounsaturated fatty acids (conventional) or high in monounsaturated fatty acids 
(premium). Values are expressed as mean ± SEM, n = 12. 
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Total HDL and buoyant HDL3b particle number concentration showed no 
significant changes with the consumption of either conventional or premium ground beef 
patties (Table 10 and Figure 8). 
 
TABLE 10 HDL particle concentrations for men and women rotated through 
test ground beefs low in monounsaturated fatty acids (conventional) 
or high in monounsaturated fatty acids (premium)1 
 Conventional 
Baseline  
Conventional 
Final 
Premium  
Baseline 
Premium  Final 
HDL Total, 
nmol/L 11256 ± 795.36 11526 ± 581.83 
11322.42 ± 
467.00 
11322.67 ± 
439.95 
     
Bouyant 
HDL3b, nmol/L 
2441.91 ± 
399.46 
2379.33 ± 
277.84 
2459.08 ± 
329.41 
4061.41 ± 
1722.05 
     
1 Data are means ± SE for 12 men and women. There were no significant differences 
among phases (P > 0.1) 
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FIGURE 8 Changes from baseline in HDL particle concentration (nmol/L) of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium). Values are 
expressed as mean ± SEM, n = 12. There were no significant differences among 
phases (P > 0.1) 
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No significant differences were seen in inflammatory markers, C-reactive protein 
(hs-CRP) or homocystine. Insulin also remained unchanged (Table 11). However, 
homocysteine concentration differed significantly between different diets (Figure 9). 
 
 
 
TABLE 11 C-reactive protein, homocysteine, and insulin levels pre- and post-test 
patty consumption1 
 Conventional Baseline 
Conventional 
Final 
Premium  
Baseline Premium  Final 
hs-CRP, mg/L 0.32 ± 0.08 
 
0.36 ±0.09 
 
 
0.40 ± 0.10 
 
 
0.30 ±0.04 
 
Insulin, uIU/ml 8.65 ± 1.61  
8.76 ±1.85 
 
9.87 ± 2.22 
 
11.92 ± 2.24 
 
Homocysteine, 
µmol/L 
9.52 ± 0.94 
 
10.60 ± 0.75 
 
10.71 ±1.07 
 
9.21 ± 0.67 
 
1 Data are means ± SE for 12 men and women. 
There were no significant differences among phases (P > 0.1) 
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Figure 9 Changes from baseline in HDL particle concentration (nmol/L) of men 
and women rotated through test ground beefs low in monounsaturated fatty acids 
(conventional) or high in monounsaturated fatty acids (premium). Values are 
expressed as mean ± SEM, n = 12. ** P ≤ 0.01 (the significant change is between 
mean differences of low and high MUFA consumption). 
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Along with lipoprotein concentration, particle density and size was also measured, but 
no significant changes were seen (Table 12). 
 
TABLE 12     Particle density and size pre- and post-test patty consumption1 
 Conventional Baseline 
Conventional 
Final 
Premium  
Baseline Premium  Final 
HDL mean 
density 
1.09 ± 0.002 
 
1.08 ±0.005 
 
1.09 ±0.002 
 
1.09 ±0.002 
 
LDL mean 
density 
1.03 ±0.0001 
 
1.02 ±0.0002** 
 
1.03 ±0.0003 
 
1.03 ±0.0003 
 
     
1 Data are means ± SE for 12 men and women. ** P ≤ 0.05 
 
While plasma concentration of palmitic acid significantly increased with 
premium ground beef consumption, linoleic acid decreased significantly after premium 
ground beef treatment. (Figure 10 and Table 13); furthermore, stearic and oleic acid 
concentration were increased after both types of beef patty treatment; however, the 
change was not statistically significant.  
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FIGURE 10 Changes from baseline in major plasma fatty acid of men and women 
rotated through test ground beefs low in monounsaturated fatty acids 
(conventional) or high in monounsaturated fatty acids (premium). Values are 
expressed as mean ± SEM, n = 12. * P ≤ 0.10; ** P ≤ 0.05 (the significant change is 
between mean differences of low and high MUFA consumption). 
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         TABLE 13     Plasma fatty acid concentrations (g/100 g fatty acids) of men and 
women rotated through test ground beefs low in monounsaturated 
fatty acids (conventional) or high in monounsaturated fatty acids 
(premium)1 
Fatty Acid 
Pre 
Conventiona
l 
Post 
Conventiona
l 
Pre Premium  Post Premium  
14:0 0.35 ± 0.05 
0.94 ± 
0.1 
0.2 ± 
0.05 
0.25 ± 
0.06 * 
16:0 24.40 ± 1.35 
25.62 ± 
2.94 
16.93 ± 
1.42 
17.50 ± 
1.55 ** 
16:1 1.72 ± 0.18 
2.13 ± 
0.30 
1.26 ± 
0.24 
1.19± 
0.20 
18:0 
 
15.22 ± 
1.93 
       
    10.08 ± 
1.48 
          
      10.48 ± 
0.45 
10.09 ± 
0.82 
18:1c9 28.62 ± 1.60 
22.53 ± 
2.43 
22.10 ± 
1.43 
20.81 ± 
0.78 
18:1c11 2.06 ± 0.16 
4.03 ± 
2.22 *** 
1.67 ± 
0.08 
1.62 ± 
0.07 
18:2 24.12 ± 2.20 
36.20 ± 
1.67 
33.54 ± 
2.02 
38.24 ± 
1.83 
18:3 0.52 ± 0.06 
0.80 ± 
0.10 
0.68 ± 
0.08 
0.66 ± 
0.07 
20:1 0.14 ± 0.02 
0.14 ± 
0.01*  
0.15 ± 
0.01 
0.22 ± 
0.01 
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TABLE 13 Continued 
Fatty Acid 
Pre 
Conventiona
l 
Post 
Conventiona
l 
Pre Premium  Post Premium  
 
20:4  4.05 ± 0.96 
10.87 ± 
1.53 
11.80 ± 
0.72 
11.97 ± 
1.00 
20:5 0.48 ± 0.06 
0.70 ± 
0.1 
0.99 ± 
0.13 
0.78 ± 
0.12 
     22:0                            0.32                     1.49                     0.47                    0.32 
                                        ±0.09                 ± 1.15                   ± 0.04                ± 0.04 
                                                                      
     22:6                            1.30                     1.97                     2.36                     2.33 
                                        ±0.28                  ± 0.37                  ± 0.19                 ± 0.30                                 
1 Data are means ± SE for 12 men and women.  
* P ≤ 0.10; ** P ≤ 0.05; ***P ≤ 0.01 
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 Tables 14 and 15 present correlations between plasma fatty acids and lipoprotein 
cholesterol concentrations. HDL cholesterol concentration was significantly decreased 
with premium ground beef consumption and was positively correlated with erucic acid 
(22:1) and negatively correlated with α-linolinic acid (18:3), linoleic (18:2) and 
eicosatetraenoic acid fatty acid (20:4). LDL cholesterol concentration was negatively 
correlated with erucic acid (22:1). Though plasma CRP level was not significant within 
each treatment, its concentration was positively correlated with oleic acid, lignocenic 
acid (24:0) and EPA, eicosapentaenoic acid (20:5). Though VLDL concentration did not 
change significantly but it was increased due to conventional ground beef diet and 
depressed with premium ground beef consumption. VLDL concentration was positively 
correlated with the trans isomer of oleic acid, elaidic acid (18:1cis11), and it was 
negatively correlated with stearic acid and oleic acid plasma concentration. HDL3 was 
negatively correlated with lignocenic acid (24:0). Furthermore, LDL mean density 
significantly increased with conventional ground beef consumption which was 
negatively correlated with linoleic acid (18:2).  
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TABLE 14 Simple correlations between plasma fatty acids and cholesterol fractions, triglycerides, hs-CRP, insulin 
and homocysteine1 
 Total Cholesterol LDL HDL TAG hs-CRP Insulin Homocysteine VLDL RLP IDL 
14:0 NC NC NC NC NC NC NC NC NC NC 
16:0 NC NC NC NC NC NC NC NC NC NC 
18:0 NC NC NC NC NC NC NC -0.34 NC NC 
18:1 NC NC NC NC 0.34 NC NC -0.38 NC NC 
18:1cis11 NC NC NC NC NC NC NC 0.98 NC NC 
18:2 NC NC -0.37 NC NC NC NC NC NC NC 
18:3 NC NC -0.38 NC NC NC NC NC NC NC 
20:4 NC NC -0.24 NC NC NC NC NC NC NC 
22:1 NC -0.58 0.30 NC NC NC NC NC NC NC 
20:5 NC NC NC NC 0.32 NC NC NC NC NC 
24:0  NC NC NC 0.32 0.34 NC NC NC NC NC 
1 The correlations are estimated by Pairwise method. All r values stated are significant, P ≤ 0.05; NC = no correlation 
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TABLE 15 Simple correlations between plasma fatty acids and cholesterol subfractions, HDL mean density, LDL 
particle size and density1 
 LDL III LDL IV HDL 2b HDL 2a HDL 3 
HDL 
mean 
density 
LDL 
mean 
density 
LDL 
mean 
size 
Lp(a) 
16:0 NC NC NC NC NC NC NC NC NC 
16:1 NC NC NC NC NC NC NC NC NC 
18:0 NC NC NC NC NC NC NC NC NC 
18:1c9 NC NC 0.29 NC NC NC NC NC NC 
18:1c11 NC 0.45 NC NC NC NC NC NC NC 
18:2 NC NC -0.34 NC NC NC -0.35 NC NC 
18:3 NC NC NC NC NC NC NC NC NC 
20:4 NC NC NC NC -0.32 NC NC NC NC 
20:5 NC NC 0.33 NC NC NC NC NC NC 
1 The correlations are estimated by Pairwise method. 
All r values stated are significant, P ≤ 0.05; NC = no correlation 
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 In order to determine whether there had been a phase effect among plasma 
lipoprotein and fatty acid concentration, the interaction between diet and phase was also 
studied. Data were analyzed by a 2-way ANOVA method using JMP statistical software.  
            LDL, HDL and total cholesterol concentration along with the rest of lipoprotein 
particles did not show a significant phase and diet interaction (Table 16 and Figures 11-
16). There was a significant change in the level of HCY due to diet; however, there is an 
interaction between phase and diet, which means changes in HCY due to diet, is not 
independent of phase (Table 17). 
            Plasma CRP level did not change significantly after either premium or 
conventional ground beef intervention; also, there was no significant phase and diet 
interaction in the level of CRP (Table 17). 
            Insulin concentration of men and women rotated through either test ground beefs, 
conventional or premium, did not change significantly after each phase and the 
interaction between diet and phase did not show a significant change as well (Table 17). 
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Table 16     Major lipoprotein plasma concentration of men and women rotated 
through test ground beefs low in monounsaturated fatty acids 
(conventional) or high in monounsaturated fatty acids (premium)1 in 
each phase and the interaction between diet and phase. 
 
 Phase 
Conventional  Premium   Effect 
Phase 
1 
Phase 
2  
Phase 
1 
Phase 
2  
Diet 
(D) 
Phase 
(P) 
D x 
P 
Total 
Cholesterol 
Baseline 
(B) 
5.62 
±0.29 
4.85 
±0.25  
5.24 
±0.44 
5.65 
±0.26     
Final (F) 5.30 ±0.35 
5.19 
±0.38  
5.30 
±0.29 
5.88 
±0.45  NS   NS     NS 
F-B 
 
-0.01 
±0.49 
-0.29 
±0.49  
-0.19 
±0.62 
-0.34 
±0.08     
LDL 
Baseline 
(B) 
 
3.43 
±0.38 
 
2.98 
±0.16 
 
 
3.12 
±0.37 
 
3.48 
±0.33 
    
Final (F) 3.42 ±0.28 
3.34 
±0.33  
3.21 
±0.25 
3.72 
±0.40  NS   NS   NS 
F-B -0.23 ±0.36 
-0.15 
±0.32  
0.12 
±0.58 
0.10 
±0.10     
HDL 
 
Baseline 
(B) 
 
1.76 
±0.36 
 
1.56 
±0.14 
 
 
1.70 
±0.15 
 
1.62 
±0.21 
    
Final (F) 1.54 ±0.15 
1.61 
±0.12  
1.75 
±0.15 
1.69 
±0.19  NS    NS   NS 
F-B 0.36 ±0.45 
0.03 
±0.19  
-0.24 
±0.18 
-0.36 
±0.15     
          
1 Data are means ± SE for 12 men and women. 
NS = not significant 
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Figure 11 Changes from baseline in total cholesterol concentration (mmol/L) of 
men and women after beef treatment in each phase. Values are expressed as mean 
± SEM; n=12. There were no significant differences among phases (P > 0.1) 
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Figure 12 Changes from baseline in total cholesterol concentration (mmol/L) of 
men and women in each phase including wash out period. Values are expressed as 
mean ± SEM; n=12. There were no significant differences among phases (P > 0.1) 
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Figure 13 Changes from baseline in HDL concentration (mmol/L) of men and 
women after beef treatment in each phase. Values are expressed as mean ± SEM; 
n=12. There were no significant differences among phases (P > 0.1) 
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Figure 14 Changes from baseline in HDL concentration (mmol/L) of men and 
women in each phase including wash out period. Values are expressed as mean ± 
SEM; n=12. There were no significant differences among phases (P > 0.1) 
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Figure 15 Changes from baseline in LDL concentration (mmol/L) of men and 
women after beef treatment in each phase. Values are expressed as mean ± SEM; 
n=12. There were no significant differences among phases (P > 0.1) 
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Figure 16 Changes from baseline in LDL concentration (mmol/L) of men and 
women in each phase including wash out period. Values are expressed as mean ± 
SEM; n=12. There were no significant differences among phases (P > 0.1) 
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Table 17        CRP, HCY and insulin concentration of men and women rotated 
through test ground beefs low in monounsaturated fatty acids (conventional) or 
high in monounsaturated fatty acids (premium)1 in each phase and the interaction 
between diet and phase 
 Phase 
Conventional  Premium   Effect 
Phase 
1 
Phase 
2  
Phase 
1 
Phase 
2  
Diet 
(D) 
Phase 
(P) 
D x 
P 
CRP 
Baseline 
(B) 
0.21 
±0.05 
0.41 
±0.12  
0.43 
±0.15 
0.35 
±0.16     
Final (F) 0.17 ±0.02 
0.51 
±0.14  
2.823 
±0.40 
0.24 
±0.47  NS NS NS 
F - B -0.04 ±0.05 
0.10 
±0.10  
-0.08 
±0.09 
-0.11 
±0.17     
HCY 
 
Baseline 
(B) 
 
7.06 
±0.28 
 
11.29 
±1.22 
 
 
11.30 
±1.37 
 
9.90 
±1.80 
    
Final (F) 10.76 ±0.90 
10.50 
±1.15  
9.60 
±1.07 
8.68 
±0.66  ** * ** 
F - B 3.70 ±1.10 
-0.78 
±0.40  
-1.70 
±1.19 
-1.22 
±1.48     
Insulin 
 
Baseline 
(B) 
 
7.62 
±1.81 
 
9.39 
±2.53 
 
 
5.72 
±0.55 
 
15.68 
±4.19 
    
Final (F) 12.82 ±3.8 
5.87 
±0.54  
13.16 
±3.54 
10.20 
±2.33  NS *** NS 
F - B 5.20 ±2.23 
-3.51 
±2.77  
7.42 
±3.69 
-5.48 
±3.43     
          
1 Data are means ± SE for 12 men and women. 
* P ≤ 0.10; ** P ≤ 0.05; ***P ≤ 0.01; NS = not significant 
 
            Major plasma fatty acids were also studied in order to test for diet and phase 
interaction. As it is shown on Table 19 there was no significant interaction between diet 
and phase in plamitic, stearic, oleic and linoleic acid (Table 18 and Figures 17-20). 
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Table 18   Major plasma fatty acid concentration of men and women rotated 
through test ground beefs low in monounsaturated fatty acids (conventional) or 
high in monounsaturated fatty acids (premium)1 in each phase and the interaction 
between diet and phase. 
Fatty acid Phase 
Conventional  Premium   Effect 
Phase 
1 
Phase 
2  
Phase 
1 
Phase 
2  
Diet 
(D) 
Phase 
(P) 
D x 
P 
Palmitic  
   Baseline 
(B) 
20.87 
±2.02 
18.32 
±2.71  
14.12 
±1.11 
15.19 
±1.73     
   Final 
(F) 
24.44 
±2.69 
25.93 
±3.87  
24.37 
±1.51 
22.63 
±3.02  NS NS NS 
   F - B 3.56 ±3.58 
7.60 
±3.80  
4.19 
±2.34 
10.47 
±3.93     
Stearic  
 
  Baseline 
(B) 
 
10.46 
±0.81 
 
21.76 
±1.16 
 
 
10.50 
±0.58 
 
20.32 
±1.35 
    
   Final 
(F) 
15.37 
±4.50 
23.24 
±3.36  
15.11 
±1.32 
19.91 
±1.63  NS NS NS 
   F - B 4.91 ±5.20 
-1.92 
±2.65  
7.42 
±1.29 
2.32 
±1.97     
Oleic 
 
Baseline 
(B) 
 
24.13 
±2.86 
 
1.56 
±0.14 
 
 
20.64 
±1.30 
 
1.62 
±0.21 
    
Final (F) 28.07 ±3.81 
1.61 
±0.12  
29.02 
±1.06 
1.69 
±0.19  NS NS NS 
F - B 3.93 ±5.84 
1.48 
±4.24  
10.56 
±1.74 
3.66 
±3.82     
Linoleic  
          
Baseline 
(B) 
29.24 
±3.34 
40.18 
±1.18  
36.00 
±2.18 
35.63 
±4.61  NS NS NS 
Final (F) 27.06 ±4.53 
35.66 
±2.53  
22.01 
±1.93 
37.94 
±0.74     
 
F - B -0.04 ±0.05 
3.66 
±9.04  
-12.45 
±2.61 
1.84 
±12.88     
          
1 Data are means ± SE for 12 men and women. 
NS = not significant 
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Figure 17 Changes from baseline in Linoleic acid concentration (g/100g fatty acid) 
of men and women after beef treatment in each phase. Values are expressed as 
mean ± SEM; n=12. There were no significant differences among phases (P > 0.1) 
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Figure 18 Changes from baseline in Oleic acid concentration (g/100g fatty acid) of 
men and women after beef treatment in each phase. Values are expressed as mean 
± SEM; n=12. There were no significant differences among phases (P > 0.1) 
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Figure 19 Changes from baseline in Palmitic acid concentration (g/100g fatty acid) 
of men and women after beef treatment in each phase. Values are expressed as 
mean ± SEM; n=12. There were no significant differences among phases (P > 0.1) 
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Figure 20 Changes from baseline in Stearic acid concentration (g/100g fatty acid) of 
men and women after beef treatment in each phase. Values are expressed as mean 
± SEM; n=12. There were no significant differences among phases (P > 0.1) 
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Discussion  
             
Diet has profound effects on the development of atherosclerosis. The importance 
of the fatty acid composition of dietary fats in coronary artery disease rates was first 
recognized by the classic Seven Countries Study (134) and the Japan-Honolulu-San 
Francisco Study (135).  Both of these cross-population studies reported that total fat, 
SFA, and cholesterol intakes were strongly and positively associated with coronary 
artery disease risk. Furthermore, they showed that MUFA intake is strongly and 
negatively associated with coronary artery disease mortality when adjustments were 
made for SFA and cholesterol. Also, it was shown that the ratio of MUFA to SFA was a 
better predictor than when each was considered separately (136). 
            Studies of the Mediterranean diet or of olive oil might incorrectly be considered 
studies of monounsaturated fatty acids. In fact, the Mediterranean diet involved a set of 
complex, nutritional components including fruits and vegetables. Furthermore, olive oil 
also includes an unsaponifiable fraction, that should be taken into consideration. In spite 
of this, the Seven Countries Study indicated there might be an inverse relationship 
between monounsaturated fatty acids and coronary mortality. Moreover, the American 
prospective studies of healthcare professionals and nurses have shown an estimated 
reduction of 19% in the risk of coronary disease when the MUFA intake was increased 
by 5% (as a percentage of the total energy intake) (83). 
            In this study, I focused on the impact of the dietary MUFA, specifically oleic 
acid (18:1, n-9) content on total lipoproteins, lipoprotein subfractions and inflammatory 
markers associated with increased CVD risk. This was implemented through a 
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comparison between the intake of conventional ground beef, and the intake of premium 
ground beef which was naturally modified to have an elevated MUFA:SFA ratio.  
            The conventional ground beef consisted of lower MUFA:SFA ratio in 
comparison to the premium ground beef in each patty; however, the total fat was higher 
in conventional ground beef. This caused total SFA and MUFA intake to be greater in 
the conventional ground beef diet as compared to premium ground beef diet.  
            In this study, I observed a significant decrease in HDL-C and an increase in 
LDL-C with premium ground beef consumption. Also, the opposite effect (although not 
significant) was seen with conventional ground beef diet. This was in contrast to 
previous studies that have shown increases in HDL-C concentration after premium 
ground beef consumption (137). However, the main difference between this study and 
the previous studies was the concentration of oleic acid in premium ground beef was 
lower than in previous studies. Because the conventional ground beef contained more 
oleic acid than the premium ground beef, these results indicate that the beneficial effect 
of oleic acid intake may be apparent even when combined with higher total fat intake 
and higher SFA.  
             It has been shown that above a certain threshold, SFA intake causes a clear 
increase in plasma HDL-C level (138). Although the physiopathological significance of 
this increase is not well established, our results were consistent in terms of HDL-C 
increase with conventional ground beef diet. In addition to the increase of HDL-C, LDL-
C decreased with conventional ground beef diet. This may be attributed to the 
concentration of oleic acid in conventional ground beef diet. Furthermore, in a different 
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study (82) it was shown that the LDL-C/HDL-C ratio is more favorably influenced by 
replacing SFA with unsaturated fatty acids than by reducing SFA alone (82).  
            An earlier study showed that a low-fat diet significantly lowered HDL-C, 
whereas high- MUFA diet did not (87). It was indicated that a solid-food diet rich in 
MUFA was equivalent to a low-fat, high-carbohydrate diet for cholesterol lowering, 
without reducing HDL-C (87). A similar response was reported in which a low-fat, high-
carbohydrate diet caused a reduction of HDL-C levels, whereas a diet high in MUFA did 
not (139).  However, neither of those studies examined the effects of higher MUFA 
intake in combination with higher total fat intake.  
            Both ground beef treatments caused a decrease in total plasma cholesterol, TAG, 
and VLDL-C. High TAG is associated with a number of adverse metabolic risk factors, 
including the preponderance of small, dense LDL (140). Furthermore, based on meta-
analysis of prospective studies from the epidemiological literature, TAG is a risk factor 
for CVD, independent of HDL-C (141). In this study lower plasma TAG after both 
conventional and premium ground beef consumption suggests a negative association 
with ground beef consumption and CVD.  Moreover, in this study the effect of ground 
beef consumption on serum cholesterol was beneficial given that total cholesterol 
concentration was depressed after both ground beef interventions. It has been found that 
each 1% rise in serum cholesterol is predicted to increase the risk of CVD by almost 2% 
(159). When VLDL TAG are hydrolyzed in plasma, the cholesterol, phospholipids, and 
proteins are transferred to higher density lipoproteins such as HDL and LDL, leaving a 
small, dense remnant lipoprotein (RLP). RLP are further metabolized to smaller, more 
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dense lipoproteins called IDL. RLP and IDL particles were measured after each ground 
beef intervention, and their plasma concentrations was decreased after both treatments. 
This also supports my contention that beef consumption in general lowers risk factors for 
CVD, given that an increase in the concentration of RLP particles is considered a risk 
factor for CVD (87, 88).  
            LDL-III decreased after both ground beef interventions, although this change was 
not statistically significant. It is believed that small, dense LDL particles are a 
contributing factor to atherosclerosis based on evidence that smaller LDL are taken up 
less readily by LDL receptors (15) are more suitable to penetrate arterial tissue (16), and 
are oxidized at a greater rate than larger LDL particles (17). There was a significant 
increase in LDL particle size after consuming conventional ground beef, suggesting that 
higher concentration of oleic acid in beef improves lipoprotein profile in men and 
women. This was confirmed by a significant increase in LDL mean density after 
conventional ground beef intervention. There was no change in LDL-IV, the densest 
form of LDL with both ground beef consumption. These results suggest that 
consumption of premium or conventional ground beef either decrease or has no effect on 
the concentration of small and dense LDL particles.  Lp(a) increased but not 
significantly after either ground beef intervention. Lp(a) is similar to LDL particles, but 
also contains apolipoprotein(a). Lp(a) particles accumulate in atherosclerotic lesions; 
therefore, it is considered to be a strong risk factor for CVD. However, Lp(a) levels are 
dependent on genetically regulated synthesis and not particle clearance. Plasma 
concentrations of HDL subfractions did not change significantly with either ground beef 
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intervention. HDL-2a cholesterol and HDL-2b cholesterol concentration decreased after 
either ground beef consumption; however, HDL-3 plasma concentration increased as did 
HDL-3 particle concentration with premium ground beef consumption. Antioxidant 
activity of HDL particles increases in the order HDL2b<HDL2a<HDL3a<HDL3b<HDL3c 
with the antioxidant activity of HDL3c most effective at the late stages of oxidation 
(142). These findings indicate that small, dense HDL particles protect LDL against 
oxidative stress, thereby, suggesting that premium ground beef consumption had 
protective effects against oxidative stress.  
            MUFA are antiatherogenic by decreasing the susceptibility of LDL to oxidation, 
improving endothelial function and reducing inflammation marker levels and platelet 
aggregation (143). In this study, premium ground beef consumption resulted in a 
decrease in the plasma CRP concentration and an increase in plasma homocysteine 
concentration  as compared to conventional ground beef consumption. This change was 
not statistically significant, but it is consistent with the notion that ground beef with a 
higher MUFA:SFA ratio can be anti-atherogenic and have anti-inflammatory effects 
through involvement of inflammatory proteins or biomarkers that are associated with 
CVD. Therefore, this study and previous studies in this laboratory lead me to conclude 
that the quality of beef fat influences the risk of CVD and inflammation.  
            The different results between each ground beef intervention and their effects on 
plasma HDL-C and LDL-C concentrations could be related to several factors, including 
participant characteristics, genetic factors and other dietary components. Furthermore, 
several other studies that have focused on the effects of high-MUFA consumption on 
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CVD and atherosclerosis risk factors have shown an improvement in the level of 
lipoproteins; however, most of those studies focused on the Mediterranean life style, 
including olive oil consumption (101) or the replacement of carbohydrate or SFA by 
MUFA in diet (87). Different results in lipoprotein concentrations in this and a previous 
study suggest that the beneficiary effects in terms of lowering risk factors for CVD 
associated with increasing MUFA:SFA ratio in ground beef can be related to other 
factors in addition to improvement of plasma HDL-C. For instance, lowering plasma 
total cholesterol, TAG, VLDL-C, RLP-C and increasing small, dense HDL3 might be 
effective in lowering risk factors for CVD. Furthermore, the amount of MUFA intake 
may be more important in terms of improving lipoprotein profile in comparison to 
dietary modification of MUFA:SFA ratio.  
   
 
 
 
 
 
 
. 
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CHAPTER III 
THE EFFECTS OF GROUND BEEF DIETS CONTAINING DIFFERENT MUFA:SFA 
RATIOS ON GENE EXPRESSION IN HUMAN PERIPHERAL BLOOD 
MONONUCLEAR CELLS 
 
Introduction             The effects of PUFA on human immune cells have been examined in several 
intervention trials (144-147) PUFA intake has been shown to decrease the expression of 
genes of liver X receptor (LXR) signaling and increase the expression of genes related to 
cellular stress responses.  In a recent study increased MUFA intake had a significant 
effect on ATP-binding cassette A1 (ABCA1) gene expression and similar effects on 
sterol regulatory element binding transcription factor 1 (SREBF1) and LXR gene 
expression compared with PUFA intake (128). In this study, peripheral blood 
mononuclear cell gene expression in response to dietary lipids was investigated.  
            Peripheral blood mononuclear cells (PBMNC) play a major role in the 
development of atherosclerosis and were chosen for this study to examine the effects of 
high-oleic acid ground beef consumption on gene expression in an intervention study.  
The genes that were selected in this study were Stearoyl-coA desaturase-1 (SCD-1), 
LDL receptor (LDLR), SREBF1, ABCA1, ATP-binding cassette G1 (ABCG1), and 
mediator complex subunit 1 (MED1). These genes are involved in lipid metabolism 
(SCD-1, LDLR and MED1) and cholesterol metabolism (SREBF1, ABCG1 and 
ABCA1).  They are also part of LXR signaling pathways and play a major role in 
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reverse cholesterol transport in macrophages and have been shown to be affected by 
different dietary fatty acids (148). 
             The selection of genes was based on their relation to atherosclerosis as well as 
the responses observed in previous studies (147).  A long-term effect of consuming 
virgin olive oil on peripheral blood mononuclear cell gene expression has been 
investigated previously (148).  In a similar study the consumption of high-fat shakes 
varying in dietary fatty acid composition was shown to alter gene expression profiles in 
PBMCs (147).   None of those studies, however, investigated the differences between a 
premium high MUFA:SFA ground beef and a conventional low MUFA:SFA ground 
beef consumption on PBMC gene expression.   
 
Stearoyl-CoA Desaturase  
             Pathway analysis has identified several candidate genes that are associated with 
fatty acid composition. For example, SCD-1 is an iron-containing enzyme that catalyzes 
a rate-limiting step in the synthesis of unsaturated fatty acids (149). SCD-1 is 
responsible for the conversion of saturated fatty acids to their Δ9 desaturated 
counterparts and can be influenced by diet. The major product of SCD is oleic acid, 
which is formed by the desaturation of stearic acid. The ratio of stearic acid to oleic acid 
has been implicated in the regulation of cell growth and differentiation through its 
effects on cell membrane fluidity and signal transduction (88, 150). A nonsynonymous 
mutation in SCD1 of Japanese-Black cattle was identified by Taniguchi and others. The 
mutation was associated with the saturation level of fatty acids and fat melting 
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temperature (151). Cattle show a dramatic change in the concentration of MUFA and the 
amount of marbling after being grain-fed. SCD1 is the main pathway involved (152). 
Even though many of the effects of SCD1 deficiency are dependent on diet composition 
and other genetic factors (59), it seems SCD1 deficiency is antiatherogenic. SCD1 
deficiency also promotes inflammation and atherosclerosis in mice (60). 
 
Adenosine Triphosphate Binding Cassette A1  
            ABCA1 is involved in the efflux of cholesterol from cells to HDL particles 
(153). Mutations in ABCA1 have also been associated with a less severe form of familial 
hypoalphalipoproteinemia (154, 155). ABCA1 and ABCG1 are two members of the 
ABC family of transporter proteins. These genes are induced in lipid-loaded 
macrophages (156). A mutation in the ABCA1 gene results in loss of function and leads 
to Tangier disease (157). Fibroblasts from Tangier patients have impaired ability to 
donate cholesterol to apolipoprotein AI (apoAI). This suggests that ABCA1 plays a 
major role in cellular cholesterol efflux. Recent studies have provided evidence that the 
nuclear receptors LXRa and LXRb mediate the lipid induction of both ABCG1 and 
ABCA1 (158).  
            The molecular mechanisms responsible for the intracellular localization, 
substrate specificity, and functional activity of ABCG1 are still poorly understood. 
ABCG1 expression is up-regulated by RXR-specific ligands as well as lipoprotein-
derived lipids, and some oxysterols (159). This mechanism takes place via the 
LXR/RXR pathway (159). The active involvement of ABCG1 in macrophage reverse 
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cholesterol transport suggests its potential role in the process of foam cell formation. 
ABCG1 may be part of a lipid transport system that counterbalances excessive influx of 
cholesterol into macrophages. Because ABCG1 is expressed ubiquitously in human 
tissues, its role in cellular lipid homeostasis may not be limited to macrophages (156). 
 
Mediator Complex Subunit 1 (MED1) 
            MED1 plays a key role in PPAR-induced adipogenesis. MED1 interacts with 
nuclear receptors such as PPARc and other transcriptional activators. Peroxisome 
proliferator-activated receptor-c, a nuclear receptor, when overexpressed in liver 
stimulates the induction of adipocyte-specific and lipogenesis-related genes and causes 
hepatic steatosis. MED1 is a key component of Mediator complex and is required for 
RNA polymerase II–dependent gene transcription (160). Mediator involves in 
transmitting signals from transcriptional activators that are also nuclear receptors.  It has 
been reported that the liver-specific knock-out of MED1 impairs the ligand-dependent 
activation of PPAR target genes (161). Furthermore, MEFs derived from MED1 KO 
embryos show reduced PPAR-mediated adipogenesis (161). MED1 is known to mediate 
strong ligand-dependent interactions between the Mediator complex and many nuclear 
receptors, including members of the PPAR family. It was demonstrated that PPAR-
mediated adipogenesis depends on MED1 (161).  
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Low Density Lipoprotein Receptor (LDLR) 
            LDLR is a cell-surface receptor that recognizes the apoprotein B100 that is 
embedded in the phospholipid outer layer of LDL particles. This receptor also 
recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). 
LDLR is associated with clathrin-coated pits, and when it binds LDL it is internalized 
into acidic endosomes where it can get separated from its ligand. The ligand then gets 
degraded in lysosomes, and the receptor returns to the cell surface (162). Mutations in 
the LDLR gene might lead to elevated plasma cholesterol levels, resulting in 
artherosclerosis and coronary heart disease (163). 
            The cholesterol that is carried by LDL and generated within the lysosome is 
known to be responsible for suppressing HMG CoA reductase activity. This suppression 
of transcription of the HMG CoA reductase gene occurs through pathways involving 
sterol regulatory element-binding protein (SREBP) (55).  Another role of the LDL-
derived cholesterol is activation of a cholesterol-esterifying enzyme, acyl CoA: 
cholesterol acyltransferase (ACAT), in order for the excess cholesterol to be stored as 
cholesteryl ester droplets in the cytoplasm (164). LDL also inhibits the SREBP pathway, 
which leads to suppression of transcription of the LDL receptor gene (55). Therefore, 
when cell cholesterol level increases, the production of LDL receptors is reduced (55). 
This role of the LDL-derived cholesterol in addition to suppression of the HMG CoA 
reductase transcription can be part of the regulatory responses that lead to a decrease 
cholesterol input from plasma as well as from endogenous synthesis (165). 
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            Objectives of this study were to determine whether Premium ground beef intake 
has an impact on the expression of genes associated with lipid and cholesterol 
metabolism in order to better understand the underlying mechanisms involved with 
CVD.  
 
Methods 
PBMC Isolation 
 PBMCs were isolated using Vacutainer Cell Preparation Tubes according to the 
manufacturer’s instruction (Plumolab Medical Supplies).  
 
RNA Extraction from White Blood Cells 
 Whole blood was centrifuged at 1690×g for 30 min.  White cells within the 
buffy coat fraction of the blood sample was collected after the centrifugation.  White 
cells was washed with phosphate buffered saline (PBS), centrifuged at 970×g for 15 min, 
resuspended in Ultra-spec, and then stored at -80ºC until RNA isolation.  Total RNA was 
then extracted from the Ultra-spec.  Total RNA concentration and purity (ratios 
A260/A280 and A260/A230) were estimated by spectrophotometry (NanoDrop ND-
1000, NanoDrop Technologies, Wilmington, DE).  
 
Reverse-transcription and Real-time qPCR 
 cDNA was generated from total RNA samples using the High Capacity cDNA 
RT Kit (Applied Biosystems, Foster City, CA), according to the manufacturer’s 
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instructions.  All generated cDNA was stored at -80ºC prior to quantification by PCR.  
Real-time PCR was completed in the Animal and Food Science Department, Texas Tech 
University, Lubbock, TX. Eukaryotic 18S rRNA was used as an endogenous gene 
expression control. 
 
Statistical Analysis 
Data were analyzed by paired t-test comparing baseline (habitual) values to 
values after 5 wk on the test diet.  Also a 2-factorial ANOVA was used by JMP (John's 
Macintosh Project) statistical software to examine the interaction between diet and phase 
with regards to each gene expression. Each participant served as her/his own control.  
Because each participant randomly rotated through all three diets, reported values are 
means ± standard error of the mean (SE) for n = 12 observations. 
 
Results 
After consuming the Premium ground beef test diet there was an increase in the 
expression of the genes ABCA1, ABCG1, LDLR and SCD-1; however, this change was 
not significant. With the exception of SCD1, all these genes were down-regulated after 
consumption of conventional ground beef. Both SREBF1 and MED1 were down-
regulated after each beef patty treatment but the effect was significantly greater after 
consuming the conventional ground beef. (Table 19, and Figures 21-22).   
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TABLE 19 Relative gene expression for men and women rotated through test 
ground beefs low in monounsaturated fatty acids (conventional) or 
high in monounsaturated fatty acids (premium)1 
Gene Conventional Baseline 
Conventional 
Final 
Premium  
Baseline Premium  Final 
ABCA 1 
 
1.56 ± 0.39 
 
 
0.89 ± 0.39 
 
 
1.61 ±0.47 
 
 
1.89 ±0.40 
 
ABCG 1 
 
2.19 ±0.56 
 
1.60 ± 0.92 
 
2.026 ± 0.57 
 
2.99 ±0.66 
 
SCD 1 
 
1.15 ± 0.34 
 
1.21 ± 0.60 
 
0.41 ±0.10 
 
  1.34 ±0.41**a 
 
SREBF 1 
 
2.04 ± 0.62 
 
 
0.20 ± 0.08***b 
 
 
1.93 ± 0.56 
 
 
1.02 ± 0.54 
 
MED 1 
 
1.22 ± 0.39 
 
0.54 ± 0.23 
 
1.54 ± 0.54 
 
1.41 ± 0.36 
 
LDLR 
 
1.26 ± 0.36 
 
0.39 ± 0.16*b 
 
1.29 ± 0.43 
 
1.52 ± 0.38 
 
1 Data are means ± SE for 12 men and women; * P ≤ 0.1; ** P ≤ 0.05; *** P ≤ 0.01 
a  p-value for the comparison between premium baseline and premium final 
b  p-value for the comparison between conventional baseline and conventional final 
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FIGURE 21  Changes from baseline in SCD1, LDLR and MED1 relative expression 
for test diets of men and women rotated through test ground beefs low in 
monounsaturated fatty acids (conventional) or high in monounsaturated fatty acids 
(premium). Values are expressed as mean ± SEM, n = 12. There were no significant 
differences among phases (P > 0.1) 
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FIGURE 22 Changes from baseline in ABCA1, ABCG1 and SREBF1 relative 
expression for test diets of men and women rotated through test ground beefs low 
in monounsaturated fatty acids (conventional) or high in monounsaturated fatty 
acids (premium). Values are expressed as mean ± SEM, n = 12. There were no 
significant differences among phases (P > 0.1) 
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In order to test for the interaction effect of diet and phase within each group of 
participant, a 2 way ANOVA was performed, the data were analyzed, and p-values were 
obtained. As it is shown in Table 20, SCD1 expression was significantly up-regulated 
with premium ground beef consumption and has a statistically significant interaction 
with phase suggesting that the result from diet is not independent of phase. Furthermore, 
other genes that were studied showed no significant phase interaction with diet effect 
(Table  20 and Figures 23-28). 
 
TABLE 20 Relative gene expression for men and women consumed test 
ground beefs low in monounsaturated fatty acids (conventional) or high in 
monounsaturated fatty acids (premium)1 in each phase and the interaction of phase 
and diet. 
Genes Phase 
Conventional  Premium   Effect 
Phase 
1 
Phase 
2  
Phase 
1 
Phase 
2  
Diet 
(D) 
Phase 
(P) 
D x 
P 
ABCA1 
Baseline 
(B) 
0.377 
±0.48 
2.33 
±0.40  
0.658 
±0.40 
2.961 
±0.48     
Final (F) 1.70 ±0.48 
0.313 
±0.40  
2.823 
±0.40 
0.583 
±0.48  NS *** NS 
F - B 2.03 ±0.98 
-2.01 
±0.56  
1.93 
±0.44 
-2.37 
±0.8     
ABCG1 
 
Baseline  
 
0.493 
±0.80 
 
3.404 
±0.67 
 
 
0.743 
±0.67 
 
3.823 
±0.80 
    
Final  3.482 ±0.80 
0.263 
±0.67  
4.627 
±0.67 
0.706 
±0.80  NS *** NS 
F - B 3.50 ±1.87 
-3.14 
±0.67  
3.68 
±0.49 
-3.11 
±0.58     
SCD1 
 
Baseline  
 
0.166 
±0.51 
 
1.853 
±0.43 
 
 
0.423 
±0.43 
 
0.396 
±0.51 
    
Final  2.829 ±0.51 
0.068 
±0.43  
1.798 
±0.43 
0.702 
±0.51  ***    *** NS 
F - B 3.03 ±0.99 
-1.78 
±0.40  
1.01 
±0.45 
0.30 
±0.56     
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TABLE 20   Continued  
Genes Phase 
Conventional  Premium   Effect 
Phase 
1 
Phase 
2  
Phase 
1 
Phase 
2  
Diet 
(D) 
Phase 
(P) 
D x 
P 
SREBF1 
 
Baseline  
 
2.140 
±0.76 
 
1.984 
±0.64 
 
 
1.204 
±0.64 
 
2.968 
±0.76 
    
Final  0.471 ±0.76 
0.016 
±0.64  
1.616 
±0.64 
0.187 
±0.76  NS NS NS 
F - B -0.69 ±1.78 
-1.96 
±0.59  
0.44 
±1.19 
-2.78 
±1.10     
MED1 
 
Baseline  
 
0.366 
±0.54 
 
1.842 
±0.45 
 
 
0.649 
±0.45 
 
2.796 
±0.54 
    
Final (F) 1.109 ±0.54 
0.135 
±0.45  
1.786 
±0.45 
0.883 
±0.54  NS *** NS 
F - B 1.35 ±0.79 
-1.70 
±0.58  
0.99 
±0.41 
-1.91 
±0.84     
LDLR1 
 
Baseline  
 
0.394 
±0.45 
 
1.879 
±0.38 
 
 
0.575 
±0.38 
 
2.295 
±0.45 
    
Final (F) 0.821 ±0.45 
0.097 
±0.38  
2.179 
±0.38 
0.598 
±0.45  NS *** NS 
F - B 1.05 ±0.78 
-1.78 
±0.49  
1.53 
±0.52 
-1.69 
±0.71     
1 Data are means ± SE for 12 men and women; *** P ≤ 0.01 
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FIGURE 23 Changes from baseline in SCD1 relative expression for test diets of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium) in each 
phase. * P ≤ 0.01 
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FIGURE 24 Changes from baseline in ABCA1 relative expression for test diets of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium) in each 
phase. Values are expressed as mean ± SEM, n = 12. There were no significant 
differences among phases (P > 0.1) 
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FIGURE 25 Changes from baseline in ABCG1 relative expression for test diets of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium) in each 
phase. Values are expressed as mean ± SEM, n = 12. There were no significant 
differences among phases (P > 0.1) 
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FIGURE 26 Changes from baseline in LDLR relative expression for test diets of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium) in each 
phase. Values are expressed as mean ± SEM, n = 12. There were no significant 
differences among phases (P > 0.1) 
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Figure 27 Changes from baseline in MED1 relative expression for test diets of men 
and women rotated through test ground beefs low in monounsaturated fatty acids 
(conventional) or high in monounsaturated fatty acids (premium) in each phase. 
Values are expressed as mean ± SEM, n = 12. There were no significant differences 
among phases (P> 0.1) 
  
96 
 
FIGURE 28 Changes from baseline in SREBF1 relative expression for test diets of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium) in each 
phase. Values are expressed as mean ± SEM, n = 12. There were no significant 
differences among phases (P > 0.1) 
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             Simple correlation among gene expression, plasma lipoproteins and fatty acids 
was obtained using multivariate Pairwise method by JMP statistical software. There 
were no significant correlations among gene expression and LDL, HDL and total 
cholesterol (Table 21). Also, other particles and fatty acids that are not listed in Table 19 
had no correlation with gene expression. There was a negative correlation between 
ABCA1 expression and myristic acid (14:0), which was also negatively correlated with 
the expression of LDLR and SREBF1. Furthermore, Lp(a) had positive correlation with 
both ABCG1 and SREBF1. There was also a negative correlation between ABCA1 
expression and the concentration of plasma HDL2a. Insulin had positive correlation with 
ABCA1 and ABCG1 gene expression (Table 21). 
 
Discussion 
 
            The effects of different fatty acids on gene expression in immune cells in humans 
has been studied through  microarray analysis as well as in an ex-vivo designed study 
(128). After postprandial consumption of milk shakes containing either 70% of energy 
from fat in the form of PUFA, saturated fatty acids, or MUFA, genes that changed 
differentially included LXR, ABCA1, SREBF1, cJUN, GSTP1, and the PPARα target 
gene PDK4 (128). PUFA, MUFA, and SFA consumption resulted in differential gene 
expression. PUFA intake decreased the expression of genes in liver X receptor signaling, 
whereas SFA intake increased the expression of these genes (128). PUFA intake also 
increased the expression of genes related to cellular stress responses. However, MUFA 
intake had an intermediate effect on several genes. For instance, the MUFA shake 
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intervention caused down-regulation on ABCA1, SREBF1 and LXR expression 6 h 
postprandially (128). 
 
 
TABLE 21 Simple correlations between gene expression, plasma major fatty 
acids, cholesterol subfractions and plasma insulin 
 VLDL HDL2a LP(a) Insulin 14:0 16:0 18:0 18:1 
ABCA1 NC -0.26 NC 0.27 -0.29 NC NC NC 
ABCG1 NC NC 0.24 0.24 NC NC NC NC 
LDLR NC NC NC NC -0.29 NC NC NC 
SCD1 -0.24 NC NC NC NC NC NC NC 
SREBF1 NC NC 0.34 NC -0.37 NC NC NC 
MED1 NC NC NC NC NC NC NC NC 
1 The correlations are estimated by Pairwise method. 
All r values stated are significant, P ≤ 0.05; NC = no correlation 
 
 
             
The comparable but lower effects observed after MUFA intake than after PUFA 
intake for some genes had been described previously after a long-term intervention of 6 
months (166). However, whole-genome microarray analyses were not performed after 
the MUFA shake intervention in those studies; therefore, conclusions regarding the total 
effects of MUFA on the whole transcriptome could not be drawn.  
            In this study I investigated many of same genes (128) to investigate the effects of 
ground beef interventions differing in MUFA:SFA ratio and total MUFA content on 
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PBMC gene expression in a cross-over study. Although it has been shown previously 
that MUFA consumption can alter expression of other genes in PBMC postprandially 
(148, 167), those studies focused on the effects of virgin olive oil on gene expression. 
Olive oil recently has been acknowledged as being more than a monounsaturated fat, due 
to its phenolic content, which provides benefits for plasma lipid concentrations and de-
presses oxidative damage (168). Therefore, none of those studies have investigated the 
interaction between MUFA intake and gene expression through dietary beef interven-
tion.  
            MUFA typically constitute 35 to 45% of the total fatty acids in beef produced in 
the U.S. (88, 93).   The major MUFA in beef, oleic acid, has been studied in more detail 
and found to lower LDL-C without affecting the beneficial HDL-C (87, 127).  However, 
the relationship between beef MUFA intake and the expression of genes related to CVD 
has not been evaluated. 
            The selection of genes in this study was based on their relation to atherosclerosis 
as well as the responses seen in previous studies. The genes that were selected in this 
study were SCD1, LDLR, SREBF1, ABCA1, ABCG1 and MED1. These genes are in-
volved in lipid metabolism (SCD1, LDLR and MED1) and cholesterol metabolism 
(SREBF1, ABCG1 and ABCA1).  They are also part of LXR signaling pathways, play a 
major role in reverse cholesterol transport in macrophages, and have been shown to be 
affected by different dietary fatty acids. After consuming the premium ground beef test 
diet, there was a small but not significant increase in the expression of the genes 
ABCA1, ABCG1, LDLR.  
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            SCD1 gene expression, however, increased significantly after consumption of the 
premium ground beef. SCD1 is responsible for the conversion of saturated fatty acids to 
their Δ9 desaturated counterparts (88, 150). The primary product of SCD is oleic acid, 
which is formed by the Δ9 desaturation of stearic acid. It was reported previously that 
hepatic Δ9 desaturation of saturated fats such as stearic acid by SCD1 was a major step 
in mediating their ability to induce hepatic lipogenesis (74). Furthermore, Enoch et al. 
(169) demonstrated that palmitoyl-CoA and stearoyl-CoA have similar substrate proper-
ties for SCD1 and that oleoyl-CoA inhibits SCD1 in rat hepatocytes. The two types of 
ground beef tested in this study provided different amounts of SCD1 substrates (palmitic 
and stearic acid). The conventional ground beef patty provided up to 10.6 g SCD1 sub-
strates and 9.7 g of potentially SCD1 inhibitory oleic acid, whereas the premium ground 
beef provided 2.9% less (7.2 g) SCD1 substrate and 1.2% less (8.3 g) inhibitory oleic 
acid. 
            These data suggest that PBMC SCD1 expression was sensitive to the composi-
tion of ground beef. When MUFA intake was high enough it had an inhibitory effect and 
could be negatively associated with SCD1 expression regardless of the higher amount of 
SFA. Thus, lower MUFA intake in the premium ground beef diet was associated with 
increase in SCD1 expression, whereas with conventional ground beef diet SCD1 expres-
sion was not affected. This occurred in the presence of higher SCD1 substrates, suggest-
ing that the inhibitory effect of oleic acid on SCD1 was independent of the amount of 
palmitic and stearic acid in diet.  
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With the exception of SCD1, all the other genes were down-regulated after con-
sumption of conventional ground beef. SREBF1 and MED1 were down-regulated after 
either beef intervention. For SREBF1, the effect was significantly greater after consum-
ing the conventional ground beef. Furthermore, LDLR expression decreased significant-
ly with the consumption of conventional ground beef and increased with premium beef 
patty consumption.   
Both LDLR and SREBF1 are involved in cholesterol metabolism (128), suggest-
ing a differential effect of conventional and premium ground beef on cholesterol me-
tabolism through LDLR and SREBF1. LDLR is associated with clathrin-coated pits, and 
when binding to LDL, it is internalized into acidic endosomes where it can be separated 
from its ligand. The cholesterol that is carried by LDL and generated within the lyso-
some is known to be responsible for suppressing HMG-CoA reductase activity. Such 
suppression of transcription of the HMG-CoA reductase gene occurs through pathways 
involving sterol regulatory element-binding protein (SREBP). LDL also inhibits the 
SREBP pathway, which leads to suppression of transcription of the LDLR gene. Sterol 
regulatory element-binding protein-1 (SREBP1) is transcription factor involved in fatty 
acid synthesis and cholesterol metabolism (170). SREBP1 is encoded by the SREBF1 
gene, which is associated with obesity, insulin resistance, type 2 diabetes and HIV-
related hyperlipoproteinemia (170-173). These results indicated that SREBF1 expression 
was significantly down-regulated after the conventional ground beef intervention, and 
the concentration ground beef contained more MUFA per patty than the premium 
ground beef. These data are consistent with the previous study in which caused a de-
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crease in SREBF1 after MUFA intake (128). Furthermore, ABCA1 and ABCG1 were 
both down-regulated with the consumption of the conventional ground beef. Though the 
change was not significant, the down-regulation of these genes was in agreement with 
the results from the previous study (128) in which postprandial gene expression after 
MUFA or PUFA intake. In that study, PUFA shake intake in vivo down-regulated the 
expression of ABCA1 and ABCG1, and similarly, PBMC ex vivo incubation with DHA 
decreased ABCA1 expression. These data were all consistent with several in vitro stud-
ies that have shown that PUFA intake can decrease the expression of ABCA1 and 
ABCG1 in macrophages (174, 175). Therefore, I conclude that MUFA intake might have 
similar effects on the genes related to cholesterol efflux that PUFA intake does. Fur-
thermore, SFA shake consumption resulted in an increased expression of genes involved 
in LXR signaling, such as ABCG1, ABCA1 and SREBF1 (128). Contrary to those data, 
consumption of conventional ground beef, which was also higher in SFA as well as 
MUFA compared to premium ground beef, caused a decrease in the expression of these 
genes. This suggests that increasing MUFA intake might diminish the negative effects of 
SFA that have been associated with CVD.  
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CHAPTER IV 
THE EFFECTS OF GROUND BEEF DIETS CONTAINING DIFFERENT MUFA:SFA 
RATIOS ON GENE EXPRESSION AND CVD MARKERS IN WOMEN WITH A 
COMPARISON TO MEN 
 
Introduction 
            Cardiovascular disease (CVD) is the leading cause of mortality and account for a 
third of all deaths of women worldwide and causes half of all deaths of women over 50 
years of age in developing countries (176). Though many important studies over the past 
two decades have developed preventive interventions and effective therapies for CVD, 
most of them included only men or limited numbers of women (177, 178). 
            Extrapolating recommendations for prevention and treatment of CVD from 
studies conducted predominantly on men to women may not be appropriate, because the 
symptoms of CVD and response to therapy are different in men and women (177, 178). 
Only recently, significant gender-related differences in prevalence, presentation and 
management of CVD have been evaluated (179). Many population studies indicated that 
total cholesterol measurements are higher in men until the fifth decade of life; however, 
women have greater values beyond this age (179). Furthermore, gender differences in 
HDL-C concentration diminish with advancing age. Women on average experience a 
relatively mild decrease in HDL-C during menopause (180, 181). Manolio et al. (182) 
reported that HDL-C was negatively associated with coronary artery disease in younger 
women and men as well as older (65 years) women (182). Despite the fact that the major 
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CVD risk factors are the same in both sexes, gender-specific differences should be taken 
into consideration. These differences are related to different outcomes in response to 
dietary interventions. There is also considerable gender-related variability in the 
prevalence and outcome related to CVD risk factors.  
            CVD still is considered to be a male disease. Rates of CVD increase with age in 
both sexes and are higher in men than in women (183). Although many studies have 
focused on the relationship between coronary disease and the effects of lowering 
cholesterol in men, there still are not sufficient recommendations for prevention of 
coronary disease that would distinguish between men and women.  
            The distribution of risk markers was shown to be different in men and women. 
Different dose responses for cholesterol, cigarette smoking, diastolic blood pressure, and 
social class in both sexes have been detected.  In despite of the similarity in relative risks 
in men and women the absolute risk are very much lower in women and the reasons 
underlying the lower incidence of CVD in women remain unclear. One contributing 
factor might be lower frequency of risk markers in women than in men. In a study done 
by Christopher G. Isles et al. (184) women compared to men smoked less and had 
similar blood pressure but women still had higher plasma cholesterol concentration. 
Furthermore, women were more likely to be obese and of lower social class. However, 
the lower level of smoking among women could not explain the difference in death rates 
because non-smoking women had only half the coronary mortality of non-smoking men 
(184).  
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            Moreover, there is evidence of sex differences in endothelial function which may 
explain differences in the prevalence of CVD in women relative to men (185, 186). 
Women have greater microvascular dysfunction relative to men (187) and chest 
discomfort and chest pain have been linked to greater endothelial dysfunction in women 
(188). There is also evidence of direct sex hormone effects on endothelial function; for 
instance, the menstrual cycle has been shown to modulate endothelial function in healthy 
women. Furthermore, many studies have indicated that there is an increase in 
endothelium-dependent vasodilation as women pass from the follicular phase to the 
luteal phase (189, 190) a period related to estrogen surge (191). Altogether, in 
comparison to healthy, age-matched men, healthy women tend to have better endothelial 
function. However, during menopause, women show a decline in endothelial function 
such that their endothelial deterioration rapidly catches up with that of men (192, 193). It 
has been found that there are specific sex differences in the expression of hormone 
receptors such as estrogen, progesterone and androgen receptors all of which have been 
found to be abundance in human vascular endothelium (194). Hormone replacement 
therapy directly stimulates endothelial receptors. It can also indirectly modify molecules 
known to affect the endothelium, e.g., lipoproteins, homocysteine (195). 
            In this study risk markers for CVD in men and women after consumption of 
different ground beef patty preparation were measured. Also, the relative expression of 
PBMC genes related to cholesterol and lipid metabolism was studied. Based on these 
data, a comparison between male and female participants was completed. The objective 
of this study was to determine a relationship between dietary fatty acids and serum 
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cholesterol, HDL, LDL and other CVD risk indicators such as the inflammatory marker 
homocysteine, CRP and insulin in men and women. In addition, the effect of dietary 
fatty acids on expression of genes related to CVD and their differences between men and 
women was evaluated to establish gender-related differences.  
 
Methods           
 Subjects  
Among subjects recruited for the study men were over age of 45 and women 
whose last menstrual period was over 1 y prior to enrollment of the study by natural or 
surgical means with or without ovaries. Subjects did not have history of CVD, stroke or 
diabetes, had normal liver function tests, normal fasting glucose, and serum total 
cholesterol of less than 6.72 mmol/L, and must not be taking lipid lowering drugs. 
Baseline characteristics of the participants are found in Table 1.  
 Statistical Analysis 
A 2-factorial analysis using JMP statistical software allowed us to see if there 
was an interaction between gender and diet. 
Results 
            There were no significant changes in the concentration of plasma LDL, HDL and 
total cholesterol within the group of male participants; however, a significant decrease 
was seen in women’s plasma HDL concentration with Premium ground beef diet (Tables 
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22-23 and Figures 29-31). Furthermore, VLDL plasma concentration increased 
significantly within male participants after conventional ground beef treatment but no 
change was seen among women (Tables 24-25 and Figures 32-33). Moreover, HDL2b 
concentration was lower after consumption in the male group. HDL2b particle 
concentration was also significantly changed with Conventional ground beef diet in the 
male group but no change was seen in the female participants regarding HDL2b plasma 
concentration. There were no significant changes in LDL particle size among women 
and men (Tables 26-27 and Figures 34-36).  
In addition to lipoprotein changes, CRP level change was also dependent on 
gender; however, there was a significant interaction between gender, phase and diet. 
Homocysteine level in women did not differ significantly when compared with men. 
Furthermore gene expression studies didn’t differ between men and women.  
 
Discussion  
            There are sex-specific differences in the processes underlying risk factor injury 
and atherosclerotic responses that are responsible for the different presentation of CVD 
in men and women. Therefore, measuring risk factors for this disease through dietary 
interventions may help elucidate these differences.  
            Women may tolerate CVD risks better than men. It has been found that, in 
women, any given level of risk marker was associated with lower CVD rates than in men 
(184). This protection might be conferred by female sex hormones. In the same study, 
even in women over age of 60, CVD rates were substantially lower than in men of 
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similar age, suggesting that natural estrogen may protect for many years beyond 
menopause (184).   
 
TABLE 22 Major lipoprotein cholesterol concentrations (mmol/L) for men 
rotated through test ground beefs low in monounsaturated fatty acids 
(Conventional) or high in monounsaturated fatty acids (Premium )1 
Lipoprotein  Conventional  Baseline 
Conventional  
Final 
Premium  
Baseline Premium  Final 
Total 
cholesterol, 
mmol/L 
5.77 ± 0.58  
 
5.30 ± 0.45 
 
5.30 ± 0.51 
 
5.10 ± 0.24 
 
LDL, mmol/L 3.93 ± 0.52  
3.47 ± 0.42 
 
3.15 ± 0.43 
 
3.26 ± 0.18 
 
HDL, mmol/L 1.36 ± 0.06   
1.52 ± 0.14 
 
1.70 ± 0.18 
 
1.52 ± 0.08 
 
1 Data are means ± SE for 5 men. 
There were no significant differences among phases (P > 0.1) 
 
 
 
 
TABLE 23 Major lipoprotein cholesterol concentrations (mmol/L) for women 
rotated through test ground beefs low in monounsaturated fatty acids 
(conventional) or high in monounsaturated fatty acids (premium)1 
Lipoprotein  Conventional  Baseline 
Conventional  
Final 
Premium  
Baseline Premium  Final 
Total 
cholesterol, 
mmol/L 
5.39 ± 0.27  
 
5.42 ± 0.30 
 
5.36 ± 0.33 
 
5.07 ± 0.31 
 
LDL, mmol/L 3.17 ± 0.17  
3.19 ± 0.19 
 
3.14 ± 0.27 
 
3.25 ± 0.31 
 
HDL, mmol/L 1.75 ± 0.17   
1.92 ± 0.25 
 
1.88 ± 0.14 
 
1.50 ± 0.09** 
 
1 Data are means ± SE for 7 women. ** P ≤ 0.05 
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Figure 29 Changes from baseline in plasma total cholesterol concentration for test 
diets of men and women rotated through test ground beefs low in monounsaturated 
fatty acids (conventional) or high in monounsaturated fatty acids (premium) in men 
and women. Values are expressed as mean ± SEM, n = 12. There were no 
significant differences among phases (P > 0.1) 
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Figure 30 Changes from baseline in plasma total LDL concentration for test diets of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium) in men and 
women. Values are expressed as mean ± SEM, n = 12. There were no significant 
differences among phases (P > 0.1) 
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Figure 31 Changes from baseline in plasma total HDL concentration for test diets 
of men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium) in men and 
women. Values are expressed as mean ± SEM, n = 12. ** P ≤ 0.05 
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TABLE 24 VLDL and HDL2b concentrations for men rotated through test 
ground beefs low in monounsaturated fatty acids (conventional) or 
high in monounsaturated fatty acids (premium)1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium  
Baseline Premium  Final 
VLDL, mmol/L 0.48 ± 0.08   
0.55 ± 0.08* 
 
0.55 ± 0.08 
 
0.54 ± 0.06 
 
HDL2b, 
mmol/L 
0.41 ± 0.07 
 
0.36 ± 0.04 
 
0.55 ± 0.10 
 
0.30 ± 0.03 
 
1 Data are means ± SE for 5 men. * P ≤ 0.1 
 
 
 
 
 
 
 
 
 
TABLE 25 VLDL and HDL2b concentrations for women rotated through test 
ground beefs low in monounsaturated fatty acids (conventional) or 
high in monounsaturated fatty acids (premium)1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium  
Baseline Premium  Final 
VLDL, mmol/L 0.85 ± 0.16   
0.77 ± 0.11 
 
0.81 ± 0.14 
 
0.79 ± 0.13 
 
HDL2b, 
mmol/L 
0.31 ± 0.04 
 
0.28 ± 0.04 
 
0.41 ± 0.06 
 
0.40 ± 0.07 
 
1 Data are means ± SE for 7 women. There were no significant differences among phases 
(P > 0.1) 
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Figure 32 Changes from baseline in plasma total VLDL concentration for test diets 
of men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium)  in men and 
women. Values are expressed as mean ± SEM, n = 12. * P ≤ 0.1 
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Figure 33 Changes from baseline in plasma total HDL-2b concentration for test 
diets of men and women rotated through test ground beefs low in monounsaturated 
fatty acids (conventional) or high in monounsaturated fatty acids (premium) in men 
and women. Values are expressed as mean ± SEM, n = 12. There were no 
significant differences among phases (P > 0.1) 
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TABLE 26 HDL and HDL2b particle concentrations and LDL particle size for 
men rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids 
(premium )1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium  
Baseline Premium  Final 
HDL, nmol/L 9791 ± 763   
10836 ± 932 
 
10522 ± 530 
 
10609 ± 431 
 
HDL2b, 
nmol/L 
1694 ± 282 
 
1935 ± 305** 
 
1930 ± 303 
 
1898 ± 220 
 
LDL (nm) 20.12 ±0.04 20.20 ±0.05 20.05 ±0.09 20.14 ±0.06 
1 Data are means ± SE for 5 men. ** P ≤ 0.05 
 
 
 
 
 
 
TABLE 27 HDL and HDL2b particle concentrations and LDL particle size for 
women rotated through test ground beefs low in monounsaturated 
fatty acids (conventional) or high in monounsaturated fatty acids 
(premium )1 
Lipoprotein  Conventional Baseline 
Conventional 
Final 
Premium  
Baseline Premium  Final 
HDL, nmol/L 12302 ± 1128   
12019 ± 743 
 
11893 ± 648 
 
11832 ± 644 
 
HDL2b, 
nmol/L 
2975 ± 591 
 
2696 ± 397 
 
2836 ± 490 
 
2749 ± 457 
 
LDL (nm) 20.11 ±0.04 20.20 ±0.04 20.13 ±0.01 20.18 ±0.04 
1 Data are means ± SE for 7 women.  
There were no significant differences among phases (P > 0.1) 
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Figure 34 Changes from baseline in plasma total HDL particle concentration for 
test diets of men and women rotated through test ground beefs low in 
monounsaturated fatty acids (conventional) or high in monounsaturated fatty acids 
(premium) in men and women. Values are expressed as mean ± SEM, n = 12. There 
were no significant differences among phases (P > 0.1) 
  
117 
 
Figure 35 Changes from baseline in plasma total HDL-2b particle concentration for 
test diets of men and women rotated through test ground beefs low in 
monounsaturated fatty acids (conventional) or high in monounsaturated fatty acids 
(premium) in men and women. Values are expressed as mean ± SEM, n = 12. ** P ≤ 
0.05 
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Figure 36 Changes from baseline in plasma total LDL particle size for test diets of 
men and women rotated through test ground beefs low in monounsaturated fatty 
acids (conventional) or high in monounsaturated fatty acids (premium) in men and 
women. Values are expressed as mean ± SEM, n = 12. There were no significant 
differences among phases (P > 0.1) 
  
119 
Several epidemiological and clinical data have provided evidence that there are 
gender-specific variations in CVD risk. Diabetes, hypothyroidism and depression 
manifest gender-related differences and are associated with increased CVD risk (196). 
Women for instance, are more likely than men to experience an episode of depression 
and are more subsequently diagnosed with the metabolic syndrome compared to men 
(196). Furthermore, studies have suggested a relationship between thyroid disease and 
coronary artery disease (197). However, the prevalence of hypothyroidism is higher in 
women and increases with age (197). 
Because the relationship between hypercholesterolemia and CVD has not yet 
been completely clarified, researchers have been investigating other potential 
contributors. Some of these contributors include sex hormones, vasodilators, vascular 
endothelial growth factor (VEGF), angiotensin II, vitamin D, plasma lipoprotein-C 
concentration, adipocyte hormones and inflammatory markers such as CRP, 
homocysteine, ferritin and insulin (198). 
 In this study, there was a significant change in HDL-C concentration with 
premium ground beef consumption. However, the change was significant in women but 
not in men suggesting that different this ground beef intervention elicited a greater 
impact in women than in men. This might have been caused by various factors that differ 
between men and women such as hormonal and/or genetic factors. In pre-menopausal 
women, endogenous female sex hormones, especially estrogens, are cardioprotective via 
multiple mechanisms including increased HDL-C, decreasing LDL-C, and release of 
vasodilators such as nitric oxide (NO) and prostacyclin (PGI2) from vessel walls. This 
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results in lowering of blood pressure and a decrease in platelet aggregation (199). 
However, after menopause, blood pressure increased in women to levels even higher 
than those observed in men (200).  In addition, in post-menopausal women, there was an 
increase in the prevalence of the metabolic syndrome, elevated body weight, 
dyslipidemia, hyperinsulinemia, and hypertension (201). Therefore, these data are in 
agreement with previous studies in that women may exhibit higher risk factors for CVD 
after menopause and in comparison to age-matched men.    
HDL2b particle concentration significantly increased after conventional ground 
beef consumption in men but no significant changes were observed in women with either 
ground beef interventions. Furthermore, VLDL-C increased significantly in men after 
consumption of conventional ground beef, whereas no significant change was seen in 
women. Several studies have shown that certain fatty acid species are preferentially 
utilized over others for VLDL assembly and secretion. For instance when McA-RH7777 
cells were cultured in the presence of exogenous oleic acid, TAG-rich VLDL were 
secreted many fold higher as compared to no oleic acid supplementation (23-25).  
My results were consistent with the previous in vitro studies given that men in 
our study showed an increase in VLDL-C with consumption of conventional ground 
beef which had higher MUFA content compared to premium ground beef. VLDL-C and 
TAG correlate strongly with LDL density and they are inversely related to HDL-C, 
especially the HDL2 subfraction (21, 22). However, these changes were as result of an 
increase in free fatty acid that was secondary to insulin resistance in those studies. In this 
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study there was no increase in TAG concentration in either men or women with either 
type of ground beef intervention. 
            Plasma CRP concentration was not significantly changed after either ground beef 
intervention in men or women, although there was an interaction between gender and 
diet on plasma CRP. There was also a significant interaction between gender, phase and 
diet. This suggests that there was a phase effect and therefore there was no significant 
differences between men and women according to different types of diet. 
            CRP is an acute-phase reactant that was originally described in 1930 (202). CRP 
was described as a CVD risk factor in men, noting that high plasma concentrations were 
associated with a two-fold increased risk of stroke and a three-fold increased risk of 
myocardial infarction (203). Further studies confirmed its efficacy as a predictive factor 
for CVD in women as well. These studies showed an increase in CRP levels above 3.0 
mg/L was associated with elevated age-adjusted incidence rates of future cardiovascular 
incidents (203). CRP did not differ between men and women (203). Therefore, data from 
our study were consistent with the previous studies given that CRP changes don’t differ 
between genders.  
            Plasma insulin concentrations were not changed by either ground beef 
intervention in either men or women. In women, insulin resistance and diabetes are 
associated with greater CVD, including up to a 6-fold increase in myocardial infarction 
risk, as compared to men (who have a four-fold increased risk of myocardial infarction 
in the setting of diabetes) (204, 205).          
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            Homocysteine, regarded as a biomarker strongly associated with CVD (35) did 
not change significantly in women or men with ground beef intervention. Elevated 
homocysteine levels are normally caused by either nutritional deficiencies in vitamin 
cofactors (folate, vitamin B12, and vitamin B6) or by genetic defects in the enzymes 
involved in homocysteine metabolism (37). These data suggest that neither conventional 
ground nor premium ground beef intake caused an increase in the pro-inflammatory 
marker, homocysteine, in either men or women. 
           No significant gender-related changes were observed in the expression of the 
genes ABCA1, ABCG1, SCD1, LDLR, MED1 and SREBF1 between men and women. 
This suggests that the significant changes in SCD1, LDLR and SREBF1 that was 
described previously was not gender-dependent.  
            Considerable research remains to be done to document the interaction between 
nutritional factors and their role in gender-related cardiovascular differences because 
several clinical observations which demonstrated the importance of sex-specific 
differences in the clinical presentation of CVD.  It is of significance to establish gender 
differences in CVD as this may avoid considerable delays in diagnosis and treatment of 
CVD in women. Furthermore, because diet has been shown to have considerable impact 
on CVD, studies comparing CVD risk factors and dietary influence in men and women 
could provide a better understanding the underlying risk factors related to CVD.  
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CHAPTER V  
CONCLUSIONS  
 
 Dietary recommendations to reduce the risk of CVD are to lower the contribution 
to daily energy intakes of total fat, SFA and trans-fatty acids, in order to avoid their 
effects on raising cholesterol levels (61). Epidemiological studies have shown that red 
meat consumption is associated with an increased risk of CVD (206, 207); however, the 
data to prove this claim remain unclear (208). Consuming moderate amounts of lean red 
meat, as part of a balanced diet, valuably contributes to intakes of essential nutrients 
iron, zinc and vitamin B12 and possibly to intakes of n-3 PUFA and conjugated linoleic 
acid (CLA).  Furthermore red meat is long established as an important dietary source of 
protein (96). However, recommendations for a “heart healthy” diet do not encourage red 
meat consumption most likely due to its saturated fat content (209). The aim of this 
study was to improve meat quality by naturally modifying the fatty acids content in beef 
and to evaluate the effects of different MUFA:SFA ratios and total MUFA content in 
beef on CVD risk factors. Six candidate genes were selected to be studied according to 
their role in cholesterol metabolism and being involved in the inflammatory pathways 
which lead to atherosclerosis. The results from each study are summarized in Table 28. 
            In the first study, a significant increase was observed in LDL-C concentration 
and a significant decrease was seen in HDL-C after premium ground beef consumption. 
LDL particle size increased significantly after consuming the conventional ground beef 
(Table 28). 
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TABLE 28 Overall effects of conventional (low-MUFA) and premium (high-
MUFA) ground beef on major cholesterol fractions, triglycerides and 
gene expression 
Study Gender  Substance Conventional ground beef  Premium ground beef 
1 
Men, 
Women Total C 
 
NC1 
 
NC 
  
 
n = 12 LDL-C 
 
NC 
 
↑ 
  
  
HDL-C 
 
NC 
 
↓ 
  
  
VLDL-C 
 
NC 
 
NC 
  
  
TAG 
 
NC 
 
NC 
  
  
LDL (nm) 
 
↑ 
 
NC 
  
  
LDL  
density 
 
↓ 
 
NC 
  
         
         
2 
Men, 
Women ABCA1 
 
NC 
 
NC 
  
 
n = 12 ABCG1 
 
NC 
 
NC 
  
  
SCD1 
 
NC 
 
↑ 
  
  
SREBF1 
 
↓ 
 
NC 
  
  
MED1 
 
NC 
 
NC 
  
  
LDLR 
 
↓ 
 
NC 
  
         
         3 Men HDL-C 
 
NC 
 
NC 
  
 
n = 5 VLDL-C 
 
↑ 
 
NC 
  
  
HDL2b 
 
↑ 
 
NC 
  
         
 
Women HDL-C 
 
NC 
 
↓ 
  
 
n = 7 VLDL-C 
 
NC 
 
NC 
      HDL2b   NC   NC     
1 NC = no change, ↑ = increased, ↓ = decreased 
 
 
 
            LDL mean density was depressed after conventional beef patty intervention. 
Other lipoproteins and cholesterol fractions did not show significant changes after either 
dietary beef interventions (Table 28). Gene expression study showed a consistent pattern 
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with lipoprotein concentration and most of the selected genes were down-regulated and 
up-regulated with conventional and premium ground beef consumption respectively. 
However, the significant changes were observed in SCD1, SREBF1 and LDLR (Table 
28). Finally, there was a significant change in HDL-C concentration with premium 
ground beef consumption. However, the change was significant in women but not in 
men. Furthermore, HDL2b particle concentration significantly increased after 
conventional ground beef consumption in men, but no changes were observed in women 
with either ground beef interventions. In addition, VLDL-C increased significantly in 
men after consumption of conventional ground beef, whereas no significant change was 
seen in women (Table 28). 
            These results have confirmed the importance of beef fatty acid influence on CVD 
risk markers. However, more studies need to be done in terms of lipoprotein 
concentration with taking into consideration the genetic and gender differences as well 
as numerous other factors including participant characteristics, life style in addition to 
dietary interventions in order to better understand the underlying mechanisms of action 
involved with CVD. 
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